
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Statistical Rigor Dashboard</title>
    <style>:root {
  --bg-color: #0f172a;
  --card-bg: rgba(30, 41, 59, 0.7);
  --accent-primary: #38bdf8;
  --accent-success: #4ade80;
  --accent-warning: #fbbf24;
  --accent-danger: #f87171;
  --text-main: #f1f5f9;
  --text-muted: #94a3b8;
  --glass-border: rgba(255, 255, 255, 0.1);
}

body {
  background-color: var(--bg-color);
  color: var(--text-main);
  font-family: 'Inter', system-ui, -apple-system, sans-serif;
  margin: 0;
  padding: 2rem;
  line-height: 1.5;
}

.container {
  max-width: 1200px;
  margin: 0 auto;
}

header {
  margin-bottom: 3rem;
  text-align: center;
}

header h1 {
  font-size: 2.5rem;
  font-weight: 800;
  background: linear-gradient(to right, var(--accent-primary), var(--accent-success));
  -webkit-background-clip: text;
  -webkit-text-fill-color: transparent;
  margin-bottom: 0.5rem;
}

header p {
  color: var(--text-muted);
  font-size: 1.1rem;
}

/* Stats Overview */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
  gap: 1.5rem;
  margin-bottom: 3rem;
}

.stat-card {
  background: var(--card-bg);
  backdrop-filter: blur(12px);
  border: 1px solid var(--glass-border);
  padding: 1.5rem;
  border-radius: 1rem;
  text-align: center;
}

.stat-value {
  display: block;
  font-size: 2.5rem;
  font-weight: 700;
  color: var(--accent-primary);
}

.stat-label {
  color: var(--text-muted);
  font-size: 0.875rem;
  text-transform: uppercase;
  letter-spacing: 0.05em;
}

/* Common Problems Section */
.problem-section {
  background: rgba(248, 113, 113, 0.1);
  border: 1px solid rgba(248, 113, 113, 0.2);
  border-radius: 1rem;
  padding: 2rem;
  margin-bottom: 3rem;
}

.problem-section h2 {
  color: var(--accent-danger);
  margin-top: 0;
  display: flex;
  align-items: center;
  gap: 0.5rem;
}

.problem-list {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
  gap: 1rem;
}

.problem-item {
  background: rgba(15, 23, 42, 0.5);
  padding: 1rem;
  border-radius: 0.5rem;
  border-left: 4px solid var(--accent-danger);
}

.problem-item b {
  color: var(--text-main);
  display: block;
  margin-bottom: 0.25rem;
}

/* Table Section */
.card {
  background: var(--card-bg);
  backdrop-filter: blur(12px);
  border: 1px solid var(--glass-border);
  border-radius: 1rem;
  overflow: hidden;
}

table {
  width: 100%;
  border-collapse: collapse;
  text-align: left;
}

th {
  background: rgba(255, 255, 255, 0.05);
  padding: 1rem;
  color: var(--text-muted);
  font-weight: 600;
  font-size: 0.875rem;
  text-transform: uppercase;
  letter-spacing: 0.05em;
}

td {
  padding: 1rem;
  border-top: 1px solid var(--glass-border);
}

.score-pill {
  padding: 0.25rem 0.75rem;
  border-radius: 9999px;
  font-weight: 600;
  font-size: 0.875rem;
}

.score-high { background: rgba(74, 222, 128, 0.2); color: #4ade80; }
.score-medium { background: rgba(251, 191, 36, 0.2); color: #fbbf24; }
.score-low { background: rgba(248, 113, 113, 0.2); color: #f87171; }

.truncate {
  max-width: 400px;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
}

.gaps-list {
  font-size: 0.875rem;
  color: var(--accent-danger);
  margin: 0;
  padding-left: 1.2rem;
}

footer {
  margin-top: 4rem;
  text-align: center;
  color: var(--text-muted);
  font-size: 0.875rem;
}
</style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Statistical Rigor Dashboard</h1>
            <p>Automated auditing of 25 scientific papers across clinical and computational domains.</p>
        </header>

        <div class="stats-grid">
            <div class="stat-card">
                <span class="stat-value">25</span>
                <span class="stat-label">Papers Audited</span>
            </div>
            <div class="stat-card" style="border-color: var(--accent-success)">
                <span class="stat-value" style="color: var(--accent-success)">1.6/10</span>
                <span class="stat-label">Average Rigor Score</span>
            </div>
            <div class="stat-card" style="border-color: var(--accent-primary)">
                <span class="stat-value">0%</span>
                <span class="stat-label">High Rigor Rate</span>
            </div>
        </div>

        <section class="problem-section">
            <h2>⚠️ Recurring Problematic Points</h2>
            <div class="problem-list">
                <div class="problem-item"><b>Sample size justification lacks explicit power calculation details.</b> Found in 24 papers</div><div class="problem-item"><b>Data exclusion criteria or justifications should be explicitly detailed.</b> Found in 21 papers</div><div class="problem-item"><b>Blinding description lacks detail on the allocation concealment process.</b> Found in 15 papers</div><div class="problem-item"><b>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</b> Found in 13 papers</div><div class="problem-item"><b>P-values reported without corresponding effect sizes or measures of magnitude.</b> Found in 11 papers</div><div class="problem-item"><b>P-values reported only as thresholds (e.g., P<0.05).</b> Found in 10 papers</div>
            </div>
        </section>

        <section class="card">
            <table>
                <thead>
                    <tr>
                        <th>Paper Title</th>
                        <th>Score</th>
                        <th>Critical Gaps</th>
                    </tr>
                </thead>
                <tbody>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Arthroscopic subacromial decompression versus placebo surgery for subacromial pain syndrome: 10 year follow-up of the FIMPACT randomised, placebo surgery controlled trialLongitudinal study of use and cost of subacromial decompression surgery: the need for effective evaluation of surgical procedures to prevent overtreatment and wasted resourcesRegional variation in low-value musculoskeletal surgery: a nationwide study from the Finnish Care RegisterAppropriate care for orthopedic patients: effect of implementation of the Clinical Practice Guideline for Diagnosis and Treatment of Subacromial Pain Syndrome in the NetherlandsCommon elective orthopaedic procedures and their clinical effectiveness: umbrella review of level 1 evidenceSubacromial decompression versus diagnostic arthroscopy for shoulder impingement: randomised, placebo surgery controlled clinical trialArthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trialSubacromial decompression versus diagnostic arthroscopy for shoulder impingement: a 5-year follow-up of a randomised, placebo surgery controlled clinical trialArthroscopic surgery compared with supervised exercises in patients with rotator cuff disease (stage II impingement syndrome)[Mid-term clinical results after surgical versus conservative treatment of subacromial impingement syndrome]Exercises versus arthroscopic decompression in patients with subacromial impingement: a randomised, controlled study in 90 cases with a one year follow upDoes arthroscopic acromioplasty provide any additional value in the treatment of shoulder impingement syndrome?: a two-year randomised controlled trialComparison of open acromioplasty, arthroscopic acromioplasty and physiotherapy in patients with subacromial impingement syndrome: a prospective randomised studyNon-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitationSubacromial decompression surgery for adults with shoulder pain: a clinical practice guidelineSubacromial decompression surgery for rotator cuff diseaseA Systematic Review of Clinical Practice Guidelines on the Diagnosis and Management of Various Shoulder DisordersCONSORT 2025 statement: updated guideline for reporting randomised trialsFinnish Subacromial Impingement Arthroscopy Controlled Trial (FIMPACT): a protocol for a randomised trial comparing arthroscopic subacromial decompression and diagnostic arthroscopy (placebo control), with an exercise therapy control, in the treatment of shoulder impingement syndromeArthroscopic subacromial decompression: analysis of one- to three-year resultsMinimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff diseaseThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionThe 15D instrument of health-related quality of life: properties and applicationsThe minimal detectable change of the Constant score in impingement, full-thickness tears, and massive rotator cuff tearsMinimal clinically important differences in ASES and simple shoulder test scores after nonoperative treatment of rotator cuff diseaseMultiple P-values and Bonferroni correctionArthroscopic decompression not recommended in the treatment of rotator cuff tendinopathy: a final review of a randomised controlled trial at a minimum follow-up of ten yearsSubacromial Decompression Yields a Better Clinical Outcome Than Therapy Alone: A Prospective Randomized Study of Patients With a Minimum 10-Year Follow-up">Arthroscopic subacromial decompression versus placebo surgery for subacromial pain syndrome: 10 year follow-up of the FIMPACT randomised, placebo surgery controlled trialLongitudinal study of use and cost of subacromial decompression surgery: the need for effective evaluation of surgical procedures to prevent overtreatment and wasted resourcesRegional variation in low-value musculoskeletal surgery: a nationwide study from the Finnish Care RegisterAppropriate care for orthopedic patients: effect of implementation of the Clinical Practice Guideline for Diagnosis and Treatment of Subacromial Pain Syndrome in the NetherlandsCommon elective orthopaedic procedures and their clinical effectiveness: umbrella review of level 1 evidenceSubacromial decompression versus diagnostic arthroscopy for shoulder impingement: randomised, placebo surgery controlled clinical trialArthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trialSubacromial decompression versus diagnostic arthroscopy for shoulder impingement: a 5-year follow-up of a randomised, placebo surgery controlled clinical trialArthroscopic surgery compared with supervised exercises in patients with rotator cuff disease (stage II impingement syndrome)[Mid-term clinical results after surgical versus conservative treatment of subacromial impingement syndrome]Exercises versus arthroscopic decompression in patients with subacromial impingement: a randomised, controlled study in 90 cases with a one year follow upDoes arthroscopic acromioplasty provide any additional value in the treatment of shoulder impingement syndrome?: a two-year randomised controlled trialComparison of open acromioplasty, arthroscopic acromioplasty and physiotherapy in patients with subacromial impingement syndrome: a prospective randomised studyNon-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitationSubacromial decompression surgery for adults with shoulder pain: a clinical practice guidelineSubacromial decompression surgery for rotator cuff diseaseA Systematic Review of Clinical Practice Guidelines on the Diagnosis and Management of Various Shoulder DisordersCONSORT 2025 statement: updated guideline for reporting randomised trialsFinnish Subacromial Impingement Arthroscopy Controlled Trial (FIMPACT): a protocol for a randomised trial comparing arthroscopic subacromial decompression and diagnostic arthroscopy (placebo control), with an exercise therapy control, in the treatment of shoulder impingement syndromeArthroscopic subacromial decompression: analysis of one- to three-year resultsMinimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff diseaseThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionThe 15D instrument of health-related quality of life: properties and applicationsThe minimal detectable change of the Constant score in impingement, full-thickness tears, and massive rotator cuff tearsMinimal clinically important differences in ASES and simple shoulder test scores after nonoperative treatment of rotator cuff diseaseMultiple P-values and Bonferroni correctionArthroscopic decompression not recommended in the treatment of rotator cuff tendinopathy: a final review of a randomised controlled trial at a minimum follow-up of ten yearsSubacromial Decompression Yields a Better Clinical Outcome Than Therapy Alone: A Prospective Randomized Study of Patients With a Minimum 10-Year Follow-up</div>
                            <small style="color: var(--text-muted)">12670246.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-medium">5.5</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Includes exploratory or post hoc analyses which may inflate type I error.</li><li>Sample size justification lacks explicit power calculation details.</li>
                                <li>...and 1 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Reporting of Factorial Randomized Trials Extension of the CONSORT 2010 StatementFactorial design considerationsReporting of randomized factorial trials was frequently inadequateFactorial trials in cardiology: pros and consAnalysis and reporting of factorial trials: a systematic reviewReporting of factorial trials of complex interventions in community settings: a systematic reviewDesign, analysis and presentation of factorial randomised controlled trialsFactorial designs: a graphical aid for choosing study designs accounting for interactionEconomic evaluation of factorial randomised controlled trials: challenges, methods and recommendationsPartial factorial trials: comparing methods for statistical analysis and economic evaluationTwo-by-two factorial cancer treatment trials: is sufficient attention being paid to possible interactions?Estimands for factorial trialsNon-factorial analyses of two-by-two factorial trial designsMonitoring futility in a two-by-two factorial design: the SPS3 experienceSimultaneous inference on treatment effects in survival studies with factorial designsFactorial design for randomized clinical trialsSome statistical considerations for design of cancer prevention trialsBias in randomised factorial trialsCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsCONSORT 2010 statement: updated guidelines for reporting parallel group randomised trialsCONSORT for reporting randomised trials in journal and conference abstractsCONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaborationReporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 StatementThe2×2 cluster randomized controlled factorial trial design is mainly used for efficiency and to explore intervention interactions: a systematic reviewAn examination of effect estimation in factorial and standardly-tailored designsImplementing clinical research using factorial designs: a primerCombining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficientlySample size estimation in phase III cancer clinical trialsAnalysis of factorial survival experimentsEvaluating how clear the questions being investigated in randomised trials are: systematic review of estimandsEstimands in published protocols of randomised trials: urgent improvement neededEstimation of treatment effects in short-term depression studies: an evaluation based on the ICH E9(R1) estimands frameworkSample size calculation in hierarchical 2×2 factorial trials with unequal cluster sizesChallenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trialsJoint testing of overall and simple effects for the two-by-two factorial trial design">Reporting of Factorial Randomized Trials Extension of the CONSORT 2010 StatementFactorial design considerationsReporting of randomized factorial trials was frequently inadequateFactorial trials in cardiology: pros and consAnalysis and reporting of factorial trials: a systematic reviewReporting of factorial trials of complex interventions in community settings: a systematic reviewDesign, analysis and presentation of factorial randomised controlled trialsFactorial designs: a graphical aid for choosing study designs accounting for interactionEconomic evaluation of factorial randomised controlled trials: challenges, methods and recommendationsPartial factorial trials: comparing methods for statistical analysis and economic evaluationTwo-by-two factorial cancer treatment trials: is sufficient attention being paid to possible interactions?Estimands for factorial trialsNon-factorial analyses of two-by-two factorial trial designsMonitoring futility in a two-by-two factorial design: the SPS3 experienceSimultaneous inference on treatment effects in survival studies with factorial designsFactorial design for randomized clinical trialsSome statistical considerations for design of cancer prevention trialsBias in randomised factorial trialsCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsCONSORT 2010 statement: updated guidelines for reporting parallel group randomised trialsCONSORT for reporting randomised trials in journal and conference abstractsCONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaborationReporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 StatementThe2×2 cluster randomized controlled factorial trial design is mainly used for efficiency and to explore intervention interactions: a systematic reviewAn examination of effect estimation in factorial and standardly-tailored designsImplementing clinical research using factorial designs: a primerCombining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficientlySample size estimation in phase III cancer clinical trialsAnalysis of factorial survival experimentsEvaluating how clear the questions being investigated in randomised trials are: systematic review of estimandsEstimands in published protocols of randomised trials: urgent improvement neededEstimation of treatment effects in short-term depression studies: an evaluation based on the ICH E9(R1) estimands frameworkSample size calculation in hierarchical 2×2 factorial trials with unequal cluster sizesChallenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trialsJoint testing of overall and simple effects for the two-by-two factorial trial design</div>
                            <small style="color: var(--text-muted)">7617336.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-medium">5.5</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>No explicit mention of missing data handling or imputation strategy.</li><li>Sample size justification lacks explicit power calculation details.</li>
                                <li>...and 1 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Cardiotropic AAV gene therapy for heart failure: a phase 1 trialHeart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of AmericaGlobal public health burden of heart failure: an updated review2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesHeart failure in humans reduces contractile force in myocardium from both ventriclesCardiac myofibrillar contractile properties during the progression from hypertension to decompensated heart failureModulation of cardiac contractility by the phospholamban/SERCA2a regulatomeCounteracting protein kinase activity in the heart: the multiple roles of protein phosphatasesType 1 phosphatase, a negative regulator of cardiac functionEnhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiologyInducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injuryAbnormal intracellular calcium handling in myocardium from patients with end-stage heart failureSarcoplasmic reticulum Ca ATPase as a therapeutic target for heart failureIncreased expression of cardiac phosphatases in patients with end-stage heart failureProtein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failureActive inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing heartsExpression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosisCardiac gene therapy with adeno-associated virus-based vectorsAAV-mediated gene therapy: advancing cardiovascular disease treatmentHuman cardiac gene therapyRescuing the failing heart by targeted gene transferIntracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trialEffects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trialsCalcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trialCardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failureA first-in-human phase 1 clinical gene therapy trial for the treatment of heart failure using a novel re-engineered adeno-associated vectorReengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscleGene therapy for the treatment of heart failure: promise postponedRoutinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction6-minute walking test: a useful tool in the management of heart failure patientsTargeting calcium regulators as therapy for heart failure: focus on the sarcoplasmic reticulum Ca-ATPase pumpCalcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca-ATPase in patients with advanced heart failureCalcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trialBarriers in heart failure gene therapy and approaches to overcome themSERCA2a protein levels are unaltered in human heart failureCombined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac stateSynergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca-ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cellsFunction and regulation of phosphatase 1 in healthy and diseased heart">Cardiotropic AAV gene therapy for heart failure: a phase 1 trialHeart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of AmericaGlobal public health burden of heart failure: an updated review2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesHeart failure in humans reduces contractile force in myocardium from both ventriclesCardiac myofibrillar contractile properties during the progression from hypertension to decompensated heart failureModulation of cardiac contractility by the phospholamban/SERCA2a regulatomeCounteracting protein kinase activity in the heart: the multiple roles of protein phosphatasesType 1 phosphatase, a negative regulator of cardiac functionEnhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiologyInducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injuryAbnormal intracellular calcium handling in myocardium from patients with end-stage heart failureSarcoplasmic reticulum Ca ATPase as a therapeutic target for heart failureIncreased expression of cardiac phosphatases in patients with end-stage heart failureProtein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failureActive inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing heartsExpression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosisCardiac gene therapy with adeno-associated virus-based vectorsAAV-mediated gene therapy: advancing cardiovascular disease treatmentHuman cardiac gene therapyRescuing the failing heart by targeted gene transferIntracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trialEffects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trialsCalcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trialCardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failureA first-in-human phase 1 clinical gene therapy trial for the treatment of heart failure using a novel re-engineered adeno-associated vectorReengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscleGene therapy for the treatment of heart failure: promise postponedRoutinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction6-minute walking test: a useful tool in the management of heart failure patientsTargeting calcium regulators as therapy for heart failure: focus on the sarcoplasmic reticulum Ca-ATPase pumpCalcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca-ATPase in patients with advanced heart failureCalcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trialBarriers in heart failure gene therapy and approaches to overcome themSERCA2a protein levels are unaltered in human heart failureCombined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac stateSynergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca-ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cellsFunction and regulation of phosphatase 1 in healthy and diseased heart</div>
                            <small style="color: var(--text-muted)">12618250.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">2.5</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Explicitly stated that no multiplicity correction or formal hypothesis testing was performed for multiple tests (e.g., nominal P-values reported).</li><li>Sample size justification lacks explicit power calculation details.</li>
                                <li>...and 3 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Spatial multiomic landscape of the human placenta at molecular resolutionAuthor Correction: Spatial multiomic landscape of the human placenta at molecular resolutionPlacenta: the forgotten organPlacental related disorders of pregnancy 2.0The placenta: a multifaceted, transient organExploring the links between cancer and placenta developmentSingle-cell reconstruction of the early maternal–fetal interface in humansA spatially resolved timeline of the human maternal–fetal interfaceSpatial multiomics map of trophoblast development in early pregnancySlide-tags enables single-nucleus barcoding for multimodal spatial genomicsThree-dimensional intact-tissue sequencing of single-cell transcriptional statesTransforming growth factor-β signaling governs the differentiation program of extravillous trophoblasts in the developing human placentaEmerging role of lymphocyte antigen-6 family of genes in cancer and immune cellsSingle-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancerThe emerging role of QSOX1 in cancerFGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinomaTargeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitorsAn alternative splicing switch regulates embryonic stem cell pluripotency and reprogrammingTriiodothyronine regulates angiogenic growth factor and cytokine secretion by isolated human decidual cells in a cell-type specific and gestational age-dependent mannerAnnexin-A1: therapeutic potential in microvascular diseaseCandesartan does not activate PPARγ and its target genes in early gestation trophoblastsDefects in placental syncytiotrophoblast cells are a common cause of developmental heart diseaseTarget prediction and validation of microRNAs expressed from FSHR and aromatase genes in human ovarian granulosa cellsExosomal miR-23b from bone marrow mesenchymal stem cells alleviates oxidative stress and pyroptosis after intracerebral hemorrhageThe FOS transcription factor family differentially controls trophoblast migration and invasionp45 NF-E2 regulates syncytiotrophoblast differentiation by post-translational GCM1 modifications in human intrauterine growth restrictionMiR-133a-3p relieves the oxidative stress induced trophoblast cell apoptosis through the BACH1/Nrf2/HO-1 signaling pathwayMSX2 safeguards syncytiotrophoblast fate of human trophoblast stem cellsMiR-655-3p inhibits growth and invasiveness of trophoblasts via targeting PBX3 and thus deteriorates preeclampsiaAssociation of lncRNA SH3PXD2A-AS1 with preeclampsia and its function in invasion and migration of placental trophoblast cellsTranscription factor AP-4 promotes tumorigenic capability and activates the Wnt/β-catenin pathway in hepatocellular carcinomaWNT and NOTCH signaling in human trophoblast development and differentiationASCL2 reciprocally controls key trophoblast lineage decisions during hemochorial placenta developmentEBF1 Gene mRNA levels in maternal blood and spontaneous preterm birthEBF1 is expressed in pericytes and contributes to pericyte cell commitmentA MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancerNR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human gliomachromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic dataE2F transcription factor 1 (E2F1) enhances the proliferation, invasion and EMT of trophoblast cells by binding to Zinc Finger E-Box Binding Homeobox 1 (ZEB1)EGF stimulates human trophoblast cell invasion by downregulating ID3-mediated KISS1 expressionThe Mesp2 transcription factor establishes segmental borders by suppressing Notch activityMesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signallingMolecular determinants of epithelial mesenchymal transition in mouse placenta and trophoblast stem cellIntegrin linked kinase regulates syncytialization of BeWo trophoblast cellsComplex patterns of GCM1 mRNA and protein in villous and extravillous trophoblast cells of the human placentaHOXA13 Is essential for placental vascular patterning and labyrinth endothelial specificationHMGA1 Is a potential driver of preeclampsia pathogenesis by interference with extravillous trophoblasts invasionChromatin potential identified by shared single-cell profiling of RNA and chromatinRole of retrotransposon-derived imprinted gene, Rtl1, in the feto-maternal interface of mouse placentaFOXF1 mediates endothelial progenitor functions and regulates vascular sproutingAberrant expression of imprinted lncRNA MEG8 causes trophoblast dysfunction and abortionLong noncoding RNA maternally expressed gene 3 improves trophoblast dysfunction and inflammation in preeclampsia through the Wnt/β-Catenin/nod-like receptor pyrin domain-containing 3 axisAberrant Kank1 expression regulates YAP to promote apoptosis and inhibit proliferation in OSCCThe polarity protein Par6 induces cell proliferation and is overexpressed in breast cancerA review of FOXI3 regulation of development and possible roles in cancer progression and metastasisTAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastomaVGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscleBone morphogenetic protein 2 promotes human trophoblast cell invasion and endothelial-like tube formation through ID1-mediated upregulation of IGF binding protein-3FOXF1 inhibits hematopoietic lineage commitment during early mesoderm specificationTBX5: a key regulator of heart developmentCellRank for directed single-cell fate mappingMusashi2 is required for the self-renewal and pluripotency of embryonic stem cellsA novel human endogenous retroviral protein inhibits cell-cell fusionThe BMP2 signaling axis promotes invasive differentiation of human trophoblastsPeroxidasin is essential for endothelial cell survival and growth signaling by sulfilimine crosslink-dependent matrix assemblyInference and analysis of cell-cell communication using CellChatThe epidermal growth factor receptor in healthy pregnancy and preeclampsiaHGF/c-Met signaling regulates early differentiation of placental trophoblast cellsExpression of pleiotrophin and its receptors in human placenta suggests roles in trophoblast life cycle and angiogenesisSyndecan-4 modulates cell polarity and migration by influencing centrosome positioning and intracellular calcium distributionSelf-renewing trophoblast organoids recapitulate the developmental program of the early human placentaNotch1 controls development of the extravillous trophoblast lineage in the human placentaCumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus RNA-seqArchR is a scalable software package for integrative single-cell chromatin accessibility analysisFast, sensitive and accurate integration of single-cell data with HarmonyOrchestrating high-throughput genomic analysis with BioconductorDemuxafy: improvement in droplet assignment by integrating multiple single-cell demultiplexing and doublet detection methodsThe UK Biobank resource with deep phenotyping and genomic dataGenome-wide association study of pre-eclampsia detects novel maternal single nucleotide polymorphisms and copy-number variants in subsets of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study cohortSurgical necrotizing enterocolitis in extremely premature neonates is associated with genetic variations in an intergenic region of chromosome 8Genetic variations and risk of placental abruption: a genome-wide association study and meta-analysis of genome-wide association studiesHeritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell typesIdentifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human geneticsActivity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbationsLD score regression distinguishes confounding from polygenicity in genome-wide association studiesMAGMA: generalized gene-set analysis of GWAS dataIntegrated analysis of multimodal single-cell dataUMAP: Uniform Manifold Approximation and ProjectionModel-based analysis of ChIP-Seq (MACS)Comparing implementations of global and local indicators of spatial associationSciPy 1.0: fundamental algorithms for scientific computing in Pythonstarfish: scalable pipelines for image-based transcriptomicsClusterMap for multi-scale clustering analysis of spatial gene expressionSCANPY: large-scale single-cell gene expression data analysisIntegration of spatial and single-cell transcriptomic data elucidates mouse organogenesis">Spatial multiomic landscape of the human placenta at molecular resolutionAuthor Correction: Spatial multiomic landscape of the human placenta at molecular resolutionPlacenta: the forgotten organPlacental related disorders of pregnancy 2.0The placenta: a multifaceted, transient organExploring the links between cancer and placenta developmentSingle-cell reconstruction of the early maternal–fetal interface in humansA spatially resolved timeline of the human maternal–fetal interfaceSpatial multiomics map of trophoblast development in early pregnancySlide-tags enables single-nucleus barcoding for multimodal spatial genomicsThree-dimensional intact-tissue sequencing of single-cell transcriptional statesTransforming growth factor-β signaling governs the differentiation program of extravillous trophoblasts in the developing human placentaEmerging role of lymphocyte antigen-6 family of genes in cancer and immune cellsSingle-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancerThe emerging role of QSOX1 in cancerFGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinomaTargeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitorsAn alternative splicing switch regulates embryonic stem cell pluripotency and reprogrammingTriiodothyronine regulates angiogenic growth factor and cytokine secretion by isolated human decidual cells in a cell-type specific and gestational age-dependent mannerAnnexin-A1: therapeutic potential in microvascular diseaseCandesartan does not activate PPARγ and its target genes in early gestation trophoblastsDefects in placental syncytiotrophoblast cells are a common cause of developmental heart diseaseTarget prediction and validation of microRNAs expressed from FSHR and aromatase genes in human ovarian granulosa cellsExosomal miR-23b from bone marrow mesenchymal stem cells alleviates oxidative stress and pyroptosis after intracerebral hemorrhageThe FOS transcription factor family differentially controls trophoblast migration and invasionp45 NF-E2 regulates syncytiotrophoblast differentiation by post-translational GCM1 modifications in human intrauterine growth restrictionMiR-133a-3p relieves the oxidative stress induced trophoblast cell apoptosis through the BACH1/Nrf2/HO-1 signaling pathwayMSX2 safeguards syncytiotrophoblast fate of human trophoblast stem cellsMiR-655-3p inhibits growth and invasiveness of trophoblasts via targeting PBX3 and thus deteriorates preeclampsiaAssociation of lncRNA SH3PXD2A-AS1 with preeclampsia and its function in invasion and migration of placental trophoblast cellsTranscription factor AP-4 promotes tumorigenic capability and activates the Wnt/β-catenin pathway in hepatocellular carcinomaWNT and NOTCH signaling in human trophoblast development and differentiationASCL2 reciprocally controls key trophoblast lineage decisions during hemochorial placenta developmentEBF1 Gene mRNA levels in maternal blood and spontaneous preterm birthEBF1 is expressed in pericytes and contributes to pericyte cell commitmentA MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancerNR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human gliomachromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic dataE2F transcription factor 1 (E2F1) enhances the proliferation, invasion and EMT of trophoblast cells by binding to Zinc Finger E-Box Binding Homeobox 1 (ZEB1)EGF stimulates human trophoblast cell invasion by downregulating ID3-mediated KISS1 expressionThe Mesp2 transcription factor establishes segmental borders by suppressing Notch activityMesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signallingMolecular determinants of epithelial mesenchymal transition in mouse placenta and trophoblast stem cellIntegrin linked kinase regulates syncytialization of BeWo trophoblast cellsComplex patterns of GCM1 mRNA and protein in villous and extravillous trophoblast cells of the human placentaHOXA13 Is essential for placental vascular patterning and labyrinth endothelial specificationHMGA1 Is a potential driver of preeclampsia pathogenesis by interference with extravillous trophoblasts invasionChromatin potential identified by shared single-cell profiling of RNA and chromatinRole of retrotransposon-derived imprinted gene, Rtl1, in the feto-maternal interface of mouse placentaFOXF1 mediates endothelial progenitor functions and regulates vascular sproutingAberrant expression of imprinted lncRNA MEG8 causes trophoblast dysfunction and abortionLong noncoding RNA maternally expressed gene 3 improves trophoblast dysfunction and inflammation in preeclampsia through the Wnt/β-Catenin/nod-like receptor pyrin domain-containing 3 axisAberrant Kank1 expression regulates YAP to promote apoptosis and inhibit proliferation in OSCCThe polarity protein Par6 induces cell proliferation and is overexpressed in breast cancerA review of FOXI3 regulation of development and possible roles in cancer progression and metastasisTAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastomaVGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscleBone morphogenetic protein 2 promotes human trophoblast cell invasion and endothelial-like tube formation through ID1-mediated upregulation of IGF binding protein-3FOXF1 inhibits hematopoietic lineage commitment during early mesoderm specificationTBX5: a key regulator of heart developmentCellRank for directed single-cell fate mappingMusashi2 is required for the self-renewal and pluripotency of embryonic stem cellsA novel human endogenous retroviral protein inhibits cell-cell fusionThe BMP2 signaling axis promotes invasive differentiation of human trophoblastsPeroxidasin is essential for endothelial cell survival and growth signaling by sulfilimine crosslink-dependent matrix assemblyInference and analysis of cell-cell communication using CellChatThe epidermal growth factor receptor in healthy pregnancy and preeclampsiaHGF/c-Met signaling regulates early differentiation of placental trophoblast cellsExpression of pleiotrophin and its receptors in human placenta suggests roles in trophoblast life cycle and angiogenesisSyndecan-4 modulates cell polarity and migration by influencing centrosome positioning and intracellular calcium distributionSelf-renewing trophoblast organoids recapitulate the developmental program of the early human placentaNotch1 controls development of the extravillous trophoblast lineage in the human placentaCumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus RNA-seqArchR is a scalable software package for integrative single-cell chromatin accessibility analysisFast, sensitive and accurate integration of single-cell data with HarmonyOrchestrating high-throughput genomic analysis with BioconductorDemuxafy: improvement in droplet assignment by integrating multiple single-cell demultiplexing and doublet detection methodsThe UK Biobank resource with deep phenotyping and genomic dataGenome-wide association study of pre-eclampsia detects novel maternal single nucleotide polymorphisms and copy-number variants in subsets of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study cohortSurgical necrotizing enterocolitis in extremely premature neonates is associated with genetic variations in an intergenic region of chromosome 8Genetic variations and risk of placental abruption: a genome-wide association study and meta-analysis of genome-wide association studiesHeritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell typesIdentifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human geneticsActivity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbationsLD score regression distinguishes confounding from polygenicity in genome-wide association studiesMAGMA: generalized gene-set analysis of GWAS dataIntegrated analysis of multimodal single-cell dataUMAP: Uniform Manifold Approximation and ProjectionModel-based analysis of ChIP-Seq (MACS)Comparing implementations of global and local indicators of spatial associationSciPy 1.0: fundamental algorithms for scientific computing in Pythonstarfish: scalable pipelines for image-based transcriptomicsClusterMap for multi-scale clustering analysis of spatial gene expressionSCANPY: large-scale single-cell gene expression data analysisIntegration of spatial and single-cell transcriptomic data elucidates mouse organogenesis</div>
                            <small style="color: var(--text-muted)">12660148.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">2.5</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Includes exploratory or post hoc analyses which may inflate type I error.</li><li>Longitudinal or clustered data structures detected without corresponding hierarchical or mixed-effects modeling.</li>
                                <li>...and 3 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialEstrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline updateHuman epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused updateESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerHuman epidermal growth factor receptor 2 testing in breast cancerRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateHER2-low breast cancer: pathological and clinical landscapeTrastuzumab deruxtecan in previously treated HER2-low advanced breast cancerAntitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib studyESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerStandardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancerClinical, pathological, and PAM50 gene expression features of HER2-low breast cancerRetrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerImpact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER databaseEstrogen-receptor-low-positive breast cancer: pathological and clinical perspectivesImpact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancerBorderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysisThe significance of highlighting the oestrogen receptor low category in breast cancerOutcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohortThe latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapyDS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1Assessment of predictive biomarkers in breast cancer: challenges and updatesOptimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancerMultidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis, and managementTrastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trialTrastuzumab deruxtecan after endocrine therapy in metastatic breast cancerDetermination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: first phase of a large-scale, multicenter global ring studyExamination of low ERBB2 protein expression in breast cancer tissue">Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialEstrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline updateHuman epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused updateESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerHuman epidermal growth factor receptor 2 testing in breast cancerRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateHER2-low breast cancer: pathological and clinical landscapeTrastuzumab deruxtecan in previously treated HER2-low advanced breast cancerAntitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib studyESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerStandardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancerClinical, pathological, and PAM50 gene expression features of HER2-low breast cancerRetrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerImpact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER databaseEstrogen-receptor-low-positive breast cancer: pathological and clinical perspectivesImpact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancerBorderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysisThe significance of highlighting the oestrogen receptor low category in breast cancerOutcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohortThe latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapyDS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1Assessment of predictive biomarkers in breast cancer: challenges and updatesOptimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancerMultidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis, and managementTrastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trialTrastuzumab deruxtecan after endocrine therapy in metastatic breast cancerDetermination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: first phase of a large-scale, multicenter global ring studyExamination of low ERBB2 protein expression in breast cancer tissue</div>
                            <small style="color: var(--text-muted)">12705423.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">2.5</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Missing data were explicitly not imputed (e.g., complete case analysis), which may introduce bias.</li>
                                <li>...and 3 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="A phase 1 randomized, placebo-controlled trial of a combination typhoid and non-typhoidal  polysaccharide conjugate vaccineA phase 1 randomized, placebo-controlled trial of a combination typhoid and non-typhoidal  polysaccharide conjugate vaccineInvasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in AfricaBacteremia among children admitted to a rural hospital in KenyaEpidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2-29 months in The GambiaCommunity-acquired bacteremia among children admitted to a rural hospital in MozambiqueInvasive Nontyphoidal Salmonella Infections Among Children in Mali, 2002-2014: Microbiological and Epidemiologic Features Guide Vaccine DevelopmentThe global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017Haemophilus influenzae Type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protectionThe global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017Introduction of Typhoid Conjugate Vaccines in Africa and AsiaDevelopment of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan AfricaSalmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidisImmunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Salmonella Glycoconjugate FormulationTyphoid conjugate vaccine gets WHO prequalificationGavi Support for Typhoid Conjugate Vaccines: Moving From Global Investments to Country IntroductionA scalable method for biochemical purification of Salmonella flagellinImmunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult miceEngineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strainsNeutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharideCross-reactivity between six Enterobacteriaceae complete lipopolysaccharide core chemotypesThe global burden and epidemiology of invasive non-typhoidal Salmonella infectionsInvasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosisGenetic changes associated with the temporal shift in invasive non-typhoidal Salmonella serovars in Bamako MaliEpidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotypeSupporting evidence for a human reservoir of invasive non-Typhoidal Salmonella from household samples in Burkina FasoDevelopment of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune responseSafety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adultsSafety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adultsVi-specific serological correlates of protection for typhoid feverDifferentiation and homing of IgA-secreting cellsGut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in HumansCritical role for beta7 integrins in formation of the gut-associated lymphoid tissueFunctional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella">A phase 1 randomized, placebo-controlled trial of a combination typhoid and non-typhoidal  polysaccharide conjugate vaccineA phase 1 randomized, placebo-controlled trial of a combination typhoid and non-typhoidal  polysaccharide conjugate vaccineInvasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in AfricaBacteremia among children admitted to a rural hospital in KenyaEpidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2-29 months in The GambiaCommunity-acquired bacteremia among children admitted to a rural hospital in MozambiqueInvasive Nontyphoidal Salmonella Infections Among Children in Mali, 2002-2014: Microbiological and Epidemiologic Features Guide Vaccine DevelopmentThe global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017Haemophilus influenzae Type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protectionThe global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017Introduction of Typhoid Conjugate Vaccines in Africa and AsiaDevelopment of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan AfricaSalmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidisImmunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Salmonella Glycoconjugate FormulationTyphoid conjugate vaccine gets WHO prequalificationGavi Support for Typhoid Conjugate Vaccines: Moving From Global Investments to Country IntroductionA scalable method for biochemical purification of Salmonella flagellinImmunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult miceEngineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strainsNeutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharideCross-reactivity between six Enterobacteriaceae complete lipopolysaccharide core chemotypesThe global burden and epidemiology of invasive non-typhoidal Salmonella infectionsInvasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosisGenetic changes associated with the temporal shift in invasive non-typhoidal Salmonella serovars in Bamako MaliEpidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotypeSupporting evidence for a human reservoir of invasive non-Typhoidal Salmonella from household samples in Burkina FasoDevelopment of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune responseSafety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adultsSafety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adultsVi-specific serological correlates of protection for typhoid feverDifferentiation and homing of IgA-secreting cellsGut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in HumansCritical role for beta7 integrins in formation of the gut-associated lymphoid tissueFunctional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella</div>
                            <small style="color: var(--text-muted)">7618460.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">2.5</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Explicitly stated that no multiplicity correction or formal hypothesis testing was performed for multiple tests (e.g., nominal P-values reported).</li><li>No explicit mention of missing data handling or imputation strategy.</li>
                                <li>...and 3 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Prostate specific antigen retesting intervals and trends in England: population based cohort studyLower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefitAn analysis of time trends in breast and prostate cancer mortality rates in Lithuania, 1986-2020Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical TrialProstate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysisGuideline of guidelines: a critical appraisal of the evidence for PSA retesting intervalsRepeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancerProstate cancer screening: Continued controversies and novel biomarker advancementsProstate-specific antigen testing rates and referral patterns from general practice data in EnglandProstate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English citiesProstate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017BLOod Test Trend for cancEr Detection (BLOTTED): protocol for an observational and prediction model development study using English primary care electronic health record dataFactors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis AuditTemporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million testsScreening for Prostate Cancer: US Preventive Services Task Force Recommendation StatementProstate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey dataA Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal DisparitiesAre we there yet? Closing the gap of prostate cancer presentation disparities in IrelandSpatio-temporal variation in prostate cancer testing in Stockholm: A population-based studyChanges in prostate specific antigen (PSA) “screening” patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old menLifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological researchProstate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort studyRisk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effectImplications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit - the ‘Fry-Turnbull’ effectUPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosisEarly Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer ScreeningThe Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer ScreeningNCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised diseaseDo Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National SurveyScreening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testingMen’s experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative studySEOM guide to primary and secondary prevention of cancer: 2014The South African Prostate Cancer Screening GuidelinesInfluence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort studyProstate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control studyBaseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysisEmpirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen">Prostate specific antigen retesting intervals and trends in England: population based cohort studyLower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefitAn analysis of time trends in breast and prostate cancer mortality rates in Lithuania, 1986-2020Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical TrialProstate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysisGuideline of guidelines: a critical appraisal of the evidence for PSA retesting intervalsRepeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancerProstate cancer screening: Continued controversies and novel biomarker advancementsProstate-specific antigen testing rates and referral patterns from general practice data in EnglandProstate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English citiesProstate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017BLOod Test Trend for cancEr Detection (BLOTTED): protocol for an observational and prediction model development study using English primary care electronic health record dataFactors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis AuditTemporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million testsScreening for Prostate Cancer: US Preventive Services Task Force Recommendation StatementProstate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey dataA Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal DisparitiesAre we there yet? Closing the gap of prostate cancer presentation disparities in IrelandSpatio-temporal variation in prostate cancer testing in Stockholm: A population-based studyChanges in prostate specific antigen (PSA) “screening” patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old menLifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological researchProstate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort studyRisk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effectImplications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit - the ‘Fry-Turnbull’ effectUPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosisEarly Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer ScreeningThe Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer ScreeningNCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised diseaseDo Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National SurveyScreening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testingMen’s experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative studySEOM guide to primary and secondary prevention of cancer: 2014The South African Prostate Cancer Screening GuidelinesInfluence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort studyProstate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control studyBaseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysisEmpirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen</div>
                            <small style="color: var(--text-muted)">12505835.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>P-values reported without corresponding effect sizes or measures of magnitude.</li>
                                <li>...and 5 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8)EXPRESSION OF CONCERN: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trialPost-myocardial infarction heart failureHeart failure after myocardial infarction: incidence and predictorsLong-term trends in the incidence of heart failure after myocardial infarctionThe effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trialIntracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trialMesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trialsTransendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialThe safety of MSC therapy over the past 15 years: a meta-analysisEffect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trialMinimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementClinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trialHuman Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) CollaborativeDelphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeuticsLong-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survivalImproved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trialIntracoronary bone marrow-derived progenitor cells in acute myocardial infarctionMajor cardiovascular events after bone marrow mononuclear cell transplantation following acute myocardial infarction: an updated post-BAMI meta-analysis of randomized controlled trialsIntracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trialIntracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trialIntracoronary injection of mononuclear bone marrow cells in acute myocardial infarctionLong term outcome after mononuclear bone marrow or peripheral blood cells infusion after myocardial infarctionSustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trialEffect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical ResultsIntracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) TrialPredictors of hospital mortality in the global registry of acute coronary eventsSex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MISex Differences in Heart Failure Following Acute Coronary SyndromesSex difference in the development and progression of heart failure after firsttime ST-elevation myocardial infarctionRandomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart FailureMesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regenerationConcise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical ApplicationsThe therapeutic potential of mesenchymal stem cells for cardiovascular diseasesCardiac Stem Cells for Myocardial Regeneration: They Are Not AloneFirst-in-human pilot trial of combined intracoronary and intravenous mesenchymal stem cell therapy in acute myocardial infarctionIs the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imagingStem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells">Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8)EXPRESSION OF CONCERN: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trialPost-myocardial infarction heart failureHeart failure after myocardial infarction: incidence and predictorsLong-term trends in the incidence of heart failure after myocardial infarctionThe effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trialIntracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trialMesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trialsTransendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialThe safety of MSC therapy over the past 15 years: a meta-analysisEffect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trialMinimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementClinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trialHuman Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) CollaborativeDelphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeuticsLong-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survivalImproved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trialIntracoronary bone marrow-derived progenitor cells in acute myocardial infarctionMajor cardiovascular events after bone marrow mononuclear cell transplantation following acute myocardial infarction: an updated post-BAMI meta-analysis of randomized controlled trialsIntracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trialIntracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trialIntracoronary injection of mononuclear bone marrow cells in acute myocardial infarctionLong term outcome after mononuclear bone marrow or peripheral blood cells infusion after myocardial infarctionSustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trialEffect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical ResultsIntracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) TrialPredictors of hospital mortality in the global registry of acute coronary eventsSex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MISex Differences in Heart Failure Following Acute Coronary SyndromesSex difference in the development and progression of heart failure after firsttime ST-elevation myocardial infarctionRandomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart FailureMesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regenerationConcise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical ApplicationsThe therapeutic potential of mesenchymal stem cells for cardiovascular diseasesCardiac Stem Cells for Myocardial Regeneration: They Are Not AloneFirst-in-human pilot trial of combined intracoronary and intravenous mesenchymal stem cell therapy in acute myocardial infarctionIs the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imagingStem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells</div>
                            <small style="color: var(--text-muted)">12570275.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Dataset mentioned as 'paired' or 'matched', but no paired statistical tests found.</li>
                                <li>...and 6 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEmergency department management and 1-year outcomes of patients with atrial flutterThe epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the emergency departmentDevelopment of a care pathway for atrial fibrillation patients in the emergency departmentCanadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency departmentOutcomes for emergency department patients with recent-onset atrial fibrillation and flutter treated in Canadian hospitalsEmergency department visits for atrial fibrillation in the United States: trends in admission rates and economic burden from 2007 to 20142025 Heart disease and stroke statistics: a report of US and global data from the American Heart AssociationVariation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departmentsEarly rhythm-control therapy in patients with atrial fibrillationBenefits of rhythm control and rate control in recent-onset atrial fibrillation: the HERMES-AF studyElectrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trialEarly or delayed cardioversion in recent-onset atrial fibrillationThe 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillationAdverse events associated with electrical cardioversion in patients with acute atrial fibrillation and atrial flutter2021 CAEP acute atrial fibrillation/flutter best practices checklistAn international view of how recent-onset atrial fibrillation is treated in the emergency departmentVernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesUse of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agentsTorsade de pointes: the clinical considerationsComparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythmMyth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency departmentConversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trialsAmiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysisEffectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysisEfficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trialsSingle oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillationOutpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approachComparison of intravenous vernakalant and electrical cardioversion in recent-onset atrial fibrillation: effect on time to restore sinus rhythm and length of hospital stayVernakalant for rapid cardioversion of recent-onset atrial fibrillation: results from the SPECTRUM studyPharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network meta-analysisSafety and effectiveness of antidysrhythmic drugs for pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and Bayesian network meta-analysisRecommendations for patient engagement in patient-oriented emergency medicine research2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillationApplying the intention-to-treat principle in practice: guidance on handling randomisation errorsImproper analysis of trials randomised using stratified blocks or minimisationThe risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studiesEmergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Resuscitation Council Guidelines 2021: adult advanced life support">Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEmergency department management and 1-year outcomes of patients with atrial flutterThe epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the emergency departmentDevelopment of a care pathway for atrial fibrillation patients in the emergency departmentCanadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency departmentOutcomes for emergency department patients with recent-onset atrial fibrillation and flutter treated in Canadian hospitalsEmergency department visits for atrial fibrillation in the United States: trends in admission rates and economic burden from 2007 to 20142025 Heart disease and stroke statistics: a report of US and global data from the American Heart AssociationVariation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departmentsEarly rhythm-control therapy in patients with atrial fibrillationBenefits of rhythm control and rate control in recent-onset atrial fibrillation: the HERMES-AF studyElectrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trialEarly or delayed cardioversion in recent-onset atrial fibrillationThe 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillationAdverse events associated with electrical cardioversion in patients with acute atrial fibrillation and atrial flutter2021 CAEP acute atrial fibrillation/flutter best practices checklistAn international view of how recent-onset atrial fibrillation is treated in the emergency departmentVernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesUse of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agentsTorsade de pointes: the clinical considerationsComparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythmMyth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency departmentConversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trialsAmiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysisEffectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysisEfficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trialsSingle oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillationOutpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approachComparison of intravenous vernakalant and electrical cardioversion in recent-onset atrial fibrillation: effect on time to restore sinus rhythm and length of hospital stayVernakalant for rapid cardioversion of recent-onset atrial fibrillation: results from the SPECTRUM studyPharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network meta-analysisSafety and effectiveness of antidysrhythmic drugs for pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and Bayesian network meta-analysisRecommendations for patient engagement in patient-oriented emergency medicine research2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillationApplying the intention-to-treat principle in practice: guidance on handling randomisation errorsImproper analysis of trials randomised using stratified blocks or minimisationThe risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studiesEmergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Resuscitation Council Guidelines 2021: adult advanced life support</div>
                            <small style="color: var(--text-muted)">12603894.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Includes exploratory or post hoc analyses which may inflate type I error.</li>
                                <li>...and 7 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulationDeep vein thrombosis and pulmonary embolismHeart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association30-year mortality after venous thromboembolism: a population-based cohort studyAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAmerican Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolismApixaban for extended treatment of venous thromboembolismOral rivaroxaban for symptomatic venous thromboembolismAnticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulantsSafety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC ProjectEmulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical TrialsTarget Trial Emulation: A Framework for Causal Inference From Observational DataInfluence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USAWarfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database AnalysisA systematic review of validated methods for identifying venous thromboembolism using administrative and claims dataAssociation of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous ThromboembolismAn automated database case definition for serious bleeding related to oral anticoagulant useStroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial FibrillationPrediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatmentA combined comorbidity score predicted mortality in elderly patients better than existing scoresPrediction Score for Anticoagulation Control Quality Among Older AdultsMeasuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty IndexMeasuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare DataUpdating International Classification of Diseases 9th Revision to 10th Revision of a Claims-Based Frailty IndexBalance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samplesA basic introduction to fixed-effect and random-effects models for meta-analysisTrends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020The statistical basis of meta-analysisHigh-dimensional propensity score adjustment in studies of treatment effects using health care claims dataCardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndromeHigh-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complicationsEffects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical examplePerformance of the High-dimensional Propensity Score in a Nordic Healthcare ModelA Proportional Hazards Model for the Subdistribution of a Competing RiskSensitivity Analysis in Observational Research: Introducing the E-ValueTransparency and Reproducibility of Observational Cohort Studies Using Large Healthcare DatabasesUse of Health Care Databases to Support Supplemental Indications of Approved MedicationsCardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort StudyAntithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trialsA randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study)Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous ThromboembolismEffectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence riskSystematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolismLong term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysisLong-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysisIncidence and mortality of venous thrombosis: a population-based studyCase fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic reviewWhen and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?Methodological considerations when analysing and interpreting real-world data">Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulationDeep vein thrombosis and pulmonary embolismHeart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association30-year mortality after venous thromboembolism: a population-based cohort studyAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAmerican Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolismApixaban for extended treatment of venous thromboembolismOral rivaroxaban for symptomatic venous thromboembolismAnticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulantsSafety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC ProjectEmulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical TrialsTarget Trial Emulation: A Framework for Causal Inference From Observational DataInfluence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USAWarfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database AnalysisA systematic review of validated methods for identifying venous thromboembolism using administrative and claims dataAssociation of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous ThromboembolismAn automated database case definition for serious bleeding related to oral anticoagulant useStroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial FibrillationPrediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatmentA combined comorbidity score predicted mortality in elderly patients better than existing scoresPrediction Score for Anticoagulation Control Quality Among Older AdultsMeasuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty IndexMeasuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare DataUpdating International Classification of Diseases 9th Revision to 10th Revision of a Claims-Based Frailty IndexBalance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samplesA basic introduction to fixed-effect and random-effects models for meta-analysisTrends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020The statistical basis of meta-analysisHigh-dimensional propensity score adjustment in studies of treatment effects using health care claims dataCardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndromeHigh-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complicationsEffects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical examplePerformance of the High-dimensional Propensity Score in a Nordic Healthcare ModelA Proportional Hazards Model for the Subdistribution of a Competing RiskSensitivity Analysis in Observational Research: Introducing the E-ValueTransparency and Reproducibility of Observational Cohort Studies Using Large Healthcare DatabasesUse of Health Care Databases to Support Supplemental Indications of Approved MedicationsCardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort StudyAntithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trialsA randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study)Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous ThromboembolismEffectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence riskSystematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolismLong term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysisLong-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysisIncidence and mortality of venous thrombosis: a population-based studyCase fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic reviewWhen and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?Methodological considerations when analysing and interpreting real-world data</div>
                            <small style="color: var(--text-muted)">12607009.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Parametric tests used without documented normality checks.</li>
                                <li>...and 6 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trialHeart failure with preserved ejection fraction: a reviewHeart failure with preserved ejection fraction:  scientific statementCharacterization of the progression from ambulatory to hospitalized heart failure with preserved ejection fractionAtrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillationCardiovascular effects of relaxin: from basic science to clinical therapyMaternal vasodilation in pregnancy: the emerging role of relaxinRelaxin family peptides and their receptorsRelaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb studySerelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialSerelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trialA randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failureEffects of serelaxin in patients with acute heart failureEffects of serelaxin in patients admitted for acute heart failure: a meta-analysisDevelopment of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failurePrevalence and prognostic significance of elevated γ-glutamyltransferase in chronic heart failureIntravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trialImpact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231)Electrolyte and water excretion in arterial hypertension. II. Studies in subjects with essential hypertension after antihypertensive drug treatmentRapid blood pressure control with minoxidil: acute and chronic effects on blood pressure, sodium excretion, and the renin-aldosterone systemHigh-output heart failure: a 15-year experienceDisconnect between the effects of serelaxin on renal function and outcome in acute heart failureAltered hemodynamics and end-organ damage in heart failure: impact on the lung and kidneyAlbumin excretion rate increases during acute myocardial infarction and strongly predicts early mortalityAlbuminuria as a marker of systemic congestion in patients with heart failureTrajectory of urine albumin-creatinine ratio in patients with acute heart failureRenal protein excretion after exercise in manProteinuria in children with febrile illnessesB-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failureEstimating left ventricular filling pressure by echocardiographyUncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesityRevivifying research on relaxin receptor-targeted therapy for cardiovascular diseasesNew creatinine- and cystatin C–based equations to estimate GFR without raceRecommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingRecommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingLeft atrial strain performance and its application in clinical practiceNormal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysisLeft atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fractionImpaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fractionLA mechanics in decompensated heart failure: insights from strain echocardiography with invasive hemodynamicsPrognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strainInterpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care:  state-of-the-art reviewEffects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial">Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trialHeart failure with preserved ejection fraction: a reviewHeart failure with preserved ejection fraction:  scientific statementCharacterization of the progression from ambulatory to hospitalized heart failure with preserved ejection fractionAtrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillationCardiovascular effects of relaxin: from basic science to clinical therapyMaternal vasodilation in pregnancy: the emerging role of relaxinRelaxin family peptides and their receptorsRelaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb studySerelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialSerelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trialA randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failureEffects of serelaxin in patients with acute heart failureEffects of serelaxin in patients admitted for acute heart failure: a meta-analysisDevelopment of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failurePrevalence and prognostic significance of elevated γ-glutamyltransferase in chronic heart failureIntravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trialImpact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231)Electrolyte and water excretion in arterial hypertension. II. Studies in subjects with essential hypertension after antihypertensive drug treatmentRapid blood pressure control with minoxidil: acute and chronic effects on blood pressure, sodium excretion, and the renin-aldosterone systemHigh-output heart failure: a 15-year experienceDisconnect between the effects of serelaxin on renal function and outcome in acute heart failureAltered hemodynamics and end-organ damage in heart failure: impact on the lung and kidneyAlbumin excretion rate increases during acute myocardial infarction and strongly predicts early mortalityAlbuminuria as a marker of systemic congestion in patients with heart failureTrajectory of urine albumin-creatinine ratio in patients with acute heart failureRenal protein excretion after exercise in manProteinuria in children with febrile illnessesB-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failureEstimating left ventricular filling pressure by echocardiographyUncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesityRevivifying research on relaxin receptor-targeted therapy for cardiovascular diseasesNew creatinine- and cystatin C–based equations to estimate GFR without raceRecommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingRecommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingLeft atrial strain performance and its application in clinical practiceNormal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysisLeft atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fractionImpaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fractionLA mechanics in decompensated heart failure: insights from strain echocardiography with invasive hemodynamicsPrognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strainInterpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care:  state-of-the-art reviewEffects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial</div>
                            <small style="color: var(--text-muted)">12618225.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Explicitly stated that no multiplicity correction or formal hypothesis testing was performed for multiple tests (e.g., nominal P-values reported).</li><li>Includes exploratory or post hoc analyses which may inflate type I error.</li>
                                <li>...and 5 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final resultsCirculating tumor DNA as a clinical test in resected pancreatic cancerAssociation of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaPancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer DatabaseOptimized anchor-modified peptides targeting mutated RAS are promising candidates for immunotherapyHigh-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12DGeneration of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoveryFrom sewer to saviour—targeting the lymphatic system to promote drug exposure and activityStructure-based programming of lymph-node targeting in molecular vaccinesLymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialMeasuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysisPersonalized RNA neoantigen vaccines stimulate T cells in pancreatic cancerRNA neoantigen vaccines prime long-lived CD8 T cells in pancreatic cancerT-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 studyPersonalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trialA neoantigen vaccine generates antitumour immunity in renal cell carcinomaCirculating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancerDistinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancerDistinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinomaEradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responsesLymph node–targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumorsVaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneityJoint confidence region estimation for area under ROC curve and Youden index">Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final resultsCirculating tumor DNA as a clinical test in resected pancreatic cancerAssociation of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaPancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer DatabaseOptimized anchor-modified peptides targeting mutated RAS are promising candidates for immunotherapyHigh-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12DGeneration of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoveryFrom sewer to saviour—targeting the lymphatic system to promote drug exposure and activityStructure-based programming of lymph-node targeting in molecular vaccinesLymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialMeasuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysisPersonalized RNA neoantigen vaccines stimulate T cells in pancreatic cancerRNA neoantigen vaccines prime long-lived CD8 T cells in pancreatic cancerT-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 studyPersonalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trialA neoantigen vaccine generates antitumour immunity in renal cell carcinomaCirculating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancerDistinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancerDistinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinomaEradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responsesLymph node–targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumorsVaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneityJoint confidence region estimation for area under ROC curve and Youden index</div>
                            <small style="color: var(--text-muted)">12618236.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Survival analysis used without documented verification of the proportional hazards assumption.</li>
                                <li>...and 4 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trialA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomesHuntington disease: natural history, biomarkers and prospects for therapeuticsFactors influencing the total functional capacity score as a critical endpoint in Huntington’s disease researchHuntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugsTetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trialSafety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseasesAntidopaminergic medication is associated with more rapidly progressive Huntington’s diseaseAntidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD)Modeling disease progression and placebo response in Huntington’s disease: insights from Enroll-HD and GENERATION HD1 cohortsPridopidine in the treatment of Huntington’s diseasePridopidine activates neuroprotective pathways impaired in Huntington diseaseThe Sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington diseasePridopidine protects neurons from mutant-huntingtin toxicity via the Sigma-1 receptorThe Sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease modelsThe Sigma-1 receptor chaperone as an inter-organelle signaling modulatorPridopidine reduces mutant huntingtin‐induced endoplasmic reticulum stress by modulation of the Sigma‐1 receptorPridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip modelSigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [F] fluspidine and [F] fallypride PET studyAdditional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington diseaseSafety and exploratory efficacy at 36 months in Open-HART, an open-label extension study of pridopidine in Huntington’s diseasePridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trialSafety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyEffects of pridopidine on functional capacity in early-stage participants from the PRIDE-HD studyPridopidine does not significantly prolong the QTc interval at the clinically relevant therapeutic doseA randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s diseaseOne-year safety and tolerability profile of pridopidine in patients with Huntington diseasePridopidine for the treatment of ALS—results from the phase 2 Healey ALS platform trial (S5.003)Motor, cognitive, and functional declines contribute to a single progressive factor in early HDAntidopaminergic medications in Huntington’s disease.Antidopaminergic medications and clinical changes in measures of Huntington’s disease: a causal analysis.Psychopathology in verified Huntington’s disease gene carriersNeuropsychiatric aspects of Huntington’s diseaseTiming and impact of psychiatric, cognitive, and motor abnormalities in Huntington diseaseThe safety profile of pridopidine, a novel Sigma-1 receptor agonist for the treatment of Huntington’s disease.Critical periods of suicide risk in Huntington’s diseaseAnalysis of responder-based endpoints: improving power through utilising continuous componentsNatural history of Huntington diseaseThe global prevalence of depression, anxiety, and sleep disorder among patients coping with post COVID-19 syndrome (long COVID): a systematic review and meta-analysisAntipsychotic prescribing to people with dementia during COVID-19Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients’ primary care records in situ using OpenSAFELYSulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteersAntipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose–response meta-analysisAntipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose–response meta-analysisA review of the important role of CYP2D6 in pharmacogenomicsThe effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteersPharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosingPridopidine for the improvement of motor function in patients with Huntington’s disease: a systematic review and meta-analysis of randomized controlled trialsPridopidine: overview of pharmacology and rationale for its use in Huntington’s diseaseMotor outcome measures in Huntington disease clinical trials.The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptorNeuronal Sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseasesImpairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington diseaseSigma-1 receptor ligands: potential in the treatment of neuropsychiatric disordersDefining clinically meaningful change on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) (P1.8-043)Safety and efficacy of laquinimod for Huntington’s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyInterrater reliability of the Unified Huntington’s Disease Rating Scale-Total Motor Score certificationAddressing bias in responder analysis of patient-reported outcomesComparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trialCo-administration of the dopaminergic stabilizer pridopidine and tetrabenazine in rats">Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trialA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomesHuntington disease: natural history, biomarkers and prospects for therapeuticsFactors influencing the total functional capacity score as a critical endpoint in Huntington’s disease researchHuntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugsTetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trialSafety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseasesAntidopaminergic medication is associated with more rapidly progressive Huntington’s diseaseAntidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD)Modeling disease progression and placebo response in Huntington’s disease: insights from Enroll-HD and GENERATION HD1 cohortsPridopidine in the treatment of Huntington’s diseasePridopidine activates neuroprotective pathways impaired in Huntington diseaseThe Sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington diseasePridopidine protects neurons from mutant-huntingtin toxicity via the Sigma-1 receptorThe Sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease modelsThe Sigma-1 receptor chaperone as an inter-organelle signaling modulatorPridopidine reduces mutant huntingtin‐induced endoplasmic reticulum stress by modulation of the Sigma‐1 receptorPridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip modelSigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [F] fluspidine and [F] fallypride PET studyAdditional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington diseaseSafety and exploratory efficacy at 36 months in Open-HART, an open-label extension study of pridopidine in Huntington’s diseasePridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trialSafety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyEffects of pridopidine on functional capacity in early-stage participants from the PRIDE-HD studyPridopidine does not significantly prolong the QTc interval at the clinically relevant therapeutic doseA randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s diseaseOne-year safety and tolerability profile of pridopidine in patients with Huntington diseasePridopidine for the treatment of ALS—results from the phase 2 Healey ALS platform trial (S5.003)Motor, cognitive, and functional declines contribute to a single progressive factor in early HDAntidopaminergic medications in Huntington’s disease.Antidopaminergic medications and clinical changes in measures of Huntington’s disease: a causal analysis.Psychopathology in verified Huntington’s disease gene carriersNeuropsychiatric aspects of Huntington’s diseaseTiming and impact of psychiatric, cognitive, and motor abnormalities in Huntington diseaseThe safety profile of pridopidine, a novel Sigma-1 receptor agonist for the treatment of Huntington’s disease.Critical periods of suicide risk in Huntington’s diseaseAnalysis of responder-based endpoints: improving power through utilising continuous componentsNatural history of Huntington diseaseThe global prevalence of depression, anxiety, and sleep disorder among patients coping with post COVID-19 syndrome (long COVID): a systematic review and meta-analysisAntipsychotic prescribing to people with dementia during COVID-19Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients’ primary care records in situ using OpenSAFELYSulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteersAntipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose–response meta-analysisAntipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose–response meta-analysisA review of the important role of CYP2D6 in pharmacogenomicsThe effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteersPharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosingPridopidine for the improvement of motor function in patients with Huntington’s disease: a systematic review and meta-analysis of randomized controlled trialsPridopidine: overview of pharmacology and rationale for its use in Huntington’s diseaseMotor outcome measures in Huntington disease clinical trials.The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptorNeuronal Sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseasesImpairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington diseaseSigma-1 receptor ligands: potential in the treatment of neuropsychiatric disordersDefining clinically meaningful change on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) (P1.8-043)Safety and efficacy of laquinimod for Huntington’s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyInterrater reliability of the Unified Huntington’s Disease Rating Scale-Total Motor Score certificationAddressing bias in responder analysis of patient-reported outcomesComparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trialCo-administration of the dopaminergic stabilizer pridopidine and tetrabenazine in rats</div>
                            <small style="color: var(--text-muted)">12618238.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Explicitly stated that no multiplicity correction or formal hypothesis testing was performed for multiple tests (e.g., nominal P-values reported).</li><li>Includes exploratory or post hoc analyses which may inflate type I error.</li>
                                <li>...and 9 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="A multimodal whole-slide foundation model for pathologyArtificial intelligence for digital and computational pathologyFine-tuning and training of DenseNet for histopathology image representation using TCGA diagnostic slidesSelf supervised contrastive learning for digital histopathologyTransformer-based unsupervised contrastive learning for histopathological image classificationRetCCL: clustering-guided contrastive learning for whole-slide image retrievalA visual–language foundation model for pathology image analysis using medical TwitterRobust and data-efficient generalization of self-supervised machine learning for diagnostic imagingTowards a general-purpose foundation model for computational pathologyA visual-language foundation model for computational pathologyA foundation model for clinical-grade computational pathology and rare cancers detectionArtificial intelligence in digital pathology—new tools for diagnosis and precision oncologyDeep learning in cancer pathology: a new generation of clinical biomarkersArtificial intelligence in histopathology: enhancing cancer research and clinical oncologyA clinical benchmark of public self-supervised pathology foundation modelsPredicting non-small cell lung cancer prognosis by fully automated microscopic pathology image featuresDeep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsiesClassification and mutation prediction from non-small cell lung cancer histopathology images using deep learningClinical-grade computational pathology using weakly supervised deep learning on whole slide imagesDeep learning can predict microsatellite instability directly from histology in gastrointestinal cancerAI-based pathology predicts origins for cancers of unknown primaryPan-cancer computational histopathology reveals mutations, tumor composition and prognosisArtificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA ChallengeA graph-transformer for whole slide image classificationDeep learning for prediction of colorectal cancer outcome: a discovery and validation studyDiagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancerTransformer-based biomarker prediction from colorectal cancer histology: a large-scale multicentric studyMultistain deep learning for prediction of prognosis and therapy response in colorectal cancerDeep learning-based classification of mesothelioma improves prediction of patient outcomeDerivation of prognostic contextual histopathological features from whole-slide images of tumours via graph deep learningGeneralizable biomarker prediction from cancer pathology slides with self-supervised deep learning: a retrospective multi-centric studyArtificial intelligence in healthcareSelf-supervised learning in medicine and healthcareReal-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detectionDeep learning in histopathology: the path to the clinicBurden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based studyContent-based multimedia information retrieval: State of the art and challengesVisual pattern mining in histology image collections using bag of featuresContent-based image retrieval of digitized histopathology in boosted spectrally embedded spacesYottixel—an image search engine for large archives of histopathology whole slide imagesFast and scalable search of whole-slide images via self-supervised deep learningHistopathological whole slide image analysis using context-based CBIRHistopathology slide indexing and search—are we there yet?Quilt-1m: one million image–text pairs for histopathologyA whole-slide foundation model for digital pathology from real-world dataGenerating dermatopathology reports from gigapixel whole slide images with HistogptData-efficient and weakly supervised computational pathology on whole-slide imagesTransmil: transformer based correlated multiple instance learning for whole slide image classificationFoundation models for fast, label-free detection of glioma infiltrationA pathology foundation model for cancer diagnosis and prognosis predictionFoundation models for generalist medical artificial intelligenceA multimodal generative AI copilot for human pathologySynthetic data in machine learning for medicine and healthcareSynthetic data in medical researchGeneration of synthetic whole-slide image tiles of tumours from RNA-sequencing data via cascaded diffusion modelsThe Cancer Genome Atlas pan-cancer analysis projectAn integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analyticsThe CPTAC data portal: a resource for cancer proteomics researchAbstract LB-242: proteomic data commons: a resource for proteogenomic analysisPathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networksDevelopment and evaluation of a deep neural network for histologic classification of renal cell carcinoma on biopsy and surgical resection slidesLeakage and the reproducibility crisis in machine-learning-based scienceOncotree: a cancer classification system for precision oncologyTCGA-Reports: a machine-readable pathology report resource for benchmarking text-based AI modelsMachine learning methods for histopathological image analysisSimilar image search for histopathology: SMILYPheochromocytoma and paragangliomaHest-1k: A dataset for spatial transcriptomics and histology image analysisImage analysis: understanding and mitigating batch effects in histopathologyDemographic bias in misdiagnosis by computational pathology modelsGenerative artificial intelligence in anatomic pathologyThe genotype-tissue expression (GTEx) projectIntegrating context for superior cancer prognosisBias in cross-entropy-based training of deep survival networksThe impact of site-specific digital histology signatures on deep learning model accuracy and biasPredicting axillary lymph node metastasis in early breast cancer using deep learning on primary tumor biopsy slidesBracs: a dataset for breast carcinoma subtyping in H&E histology imagesThe Digital Brain Tumour Atlas, an open histopathology resourceCAD systems for colorectal cancer from WSI are still not ready for clinical acceptanceiMIL4PATH: a semi-supervised interpretable approach for colorectal whole-slide imagesAn interpretable machine learning system for colorectal cancer diagnosis from pathology slidesClear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expressionIntratumoral resolution of driver gene mutation heterogeneity in renal cancer using deep learningWeakly supervised joint whole-slide segmentation and classification in prostate cancerMultimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer">A multimodal whole-slide foundation model for pathologyArtificial intelligence for digital and computational pathologyFine-tuning and training of DenseNet for histopathology image representation using TCGA diagnostic slidesSelf supervised contrastive learning for digital histopathologyTransformer-based unsupervised contrastive learning for histopathological image classificationRetCCL: clustering-guided contrastive learning for whole-slide image retrievalA visual–language foundation model for pathology image analysis using medical TwitterRobust and data-efficient generalization of self-supervised machine learning for diagnostic imagingTowards a general-purpose foundation model for computational pathologyA visual-language foundation model for computational pathologyA foundation model for clinical-grade computational pathology and rare cancers detectionArtificial intelligence in digital pathology—new tools for diagnosis and precision oncologyDeep learning in cancer pathology: a new generation of clinical biomarkersArtificial intelligence in histopathology: enhancing cancer research and clinical oncologyA clinical benchmark of public self-supervised pathology foundation modelsPredicting non-small cell lung cancer prognosis by fully automated microscopic pathology image featuresDeep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsiesClassification and mutation prediction from non-small cell lung cancer histopathology images using deep learningClinical-grade computational pathology using weakly supervised deep learning on whole slide imagesDeep learning can predict microsatellite instability directly from histology in gastrointestinal cancerAI-based pathology predicts origins for cancers of unknown primaryPan-cancer computational histopathology reveals mutations, tumor composition and prognosisArtificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA ChallengeA graph-transformer for whole slide image classificationDeep learning for prediction of colorectal cancer outcome: a discovery and validation studyDiagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancerTransformer-based biomarker prediction from colorectal cancer histology: a large-scale multicentric studyMultistain deep learning for prediction of prognosis and therapy response in colorectal cancerDeep learning-based classification of mesothelioma improves prediction of patient outcomeDerivation of prognostic contextual histopathological features from whole-slide images of tumours via graph deep learningGeneralizable biomarker prediction from cancer pathology slides with self-supervised deep learning: a retrospective multi-centric studyArtificial intelligence in healthcareSelf-supervised learning in medicine and healthcareReal-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detectionDeep learning in histopathology: the path to the clinicBurden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based studyContent-based multimedia information retrieval: State of the art and challengesVisual pattern mining in histology image collections using bag of featuresContent-based image retrieval of digitized histopathology in boosted spectrally embedded spacesYottixel—an image search engine for large archives of histopathology whole slide imagesFast and scalable search of whole-slide images via self-supervised deep learningHistopathological whole slide image analysis using context-based CBIRHistopathology slide indexing and search—are we there yet?Quilt-1m: one million image–text pairs for histopathologyA whole-slide foundation model for digital pathology from real-world dataGenerating dermatopathology reports from gigapixel whole slide images with HistogptData-efficient and weakly supervised computational pathology on whole-slide imagesTransmil: transformer based correlated multiple instance learning for whole slide image classificationFoundation models for fast, label-free detection of glioma infiltrationA pathology foundation model for cancer diagnosis and prognosis predictionFoundation models for generalist medical artificial intelligenceA multimodal generative AI copilot for human pathologySynthetic data in machine learning for medicine and healthcareSynthetic data in medical researchGeneration of synthetic whole-slide image tiles of tumours from RNA-sequencing data via cascaded diffusion modelsThe Cancer Genome Atlas pan-cancer analysis projectAn integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analyticsThe CPTAC data portal: a resource for cancer proteomics researchAbstract LB-242: proteomic data commons: a resource for proteogenomic analysisPathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networksDevelopment and evaluation of a deep neural network for histologic classification of renal cell carcinoma on biopsy and surgical resection slidesLeakage and the reproducibility crisis in machine-learning-based scienceOncotree: a cancer classification system for precision oncologyTCGA-Reports: a machine-readable pathology report resource for benchmarking text-based AI modelsMachine learning methods for histopathological image analysisSimilar image search for histopathology: SMILYPheochromocytoma and paragangliomaHest-1k: A dataset for spatial transcriptomics and histology image analysisImage analysis: understanding and mitigating batch effects in histopathologyDemographic bias in misdiagnosis by computational pathology modelsGenerative artificial intelligence in anatomic pathologyThe genotype-tissue expression (GTEx) projectIntegrating context for superior cancer prognosisBias in cross-entropy-based training of deep survival networksThe impact of site-specific digital histology signatures on deep learning model accuracy and biasPredicting axillary lymph node metastasis in early breast cancer using deep learning on primary tumor biopsy slidesBracs: a dataset for breast carcinoma subtyping in H&E histology imagesThe Digital Brain Tumour Atlas, an open histopathology resourceCAD systems for colorectal cancer from WSI are still not ready for clinical acceptanceiMIL4PATH: a semi-supervised interpretable approach for colorectal whole-slide imagesAn interpretable machine learning system for colorectal cancer diagnosis from pathology slidesClear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expressionIntratumoral resolution of driver gene mutation heterogeneity in renal cancer using deep learningWeakly supervised joint whole-slide segmentation and classification in prostate cancerMultimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer</div>
                            <small style="color: var(--text-muted)">12618242.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Includes exploratory or post hoc analyses which may inflate type I error.</li><li>P-values reported without corresponding effect sizes or measures of magnitude.</li>
                                <li>...and 5 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trialProtected to death: systematic exclusion of pregnant women from Ebola virus disease trialsSafety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in AfricaSafety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trialSafety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trialSafety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trialNonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidateMonitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola vaccination campaignSmall babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve countingNational and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010Vaccination during pregnancy: current and possible future recommendationsImmunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartumPlacental transfer of antibody and its relationship to vaccination in pregnancySafety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trialLeapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in RwandaMaternal death: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataSpontaneous abortion and ectopic pregnancy: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety dataStillbirth: case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety dataPathways to preterm birth: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataHypertensive disorders of pregnancy: case definitions & guidelines for data collection, analysis, and presentation of immunization safety dataAntenatal bleeding: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataPostpartum haemorrhage: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataCongenital anomalies: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataSmall for gestational age: case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety dataLow birth weight: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety dataPreterm birth: case definition & guidelines for data collection, analysis, and presentation of immunisation safety dataNeonatal death: case definition & guidelines for data collection, analysis, and presentation of immunization safety dataFailure to thrive: case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data">Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trialProtected to death: systematic exclusion of pregnant women from Ebola virus disease trialsSafety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in AfricaSafety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trialSafety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trialSafety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trialNonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidateMonitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola vaccination campaignSmall babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve countingNational and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010Vaccination during pregnancy: current and possible future recommendationsImmunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartumPlacental transfer of antibody and its relationship to vaccination in pregnancySafety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trialLeapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in RwandaMaternal death: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataSpontaneous abortion and ectopic pregnancy: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety dataStillbirth: case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety dataPathways to preterm birth: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataHypertensive disorders of pregnancy: case definitions & guidelines for data collection, analysis, and presentation of immunization safety dataAntenatal bleeding: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataPostpartum haemorrhage: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataCongenital anomalies: case definition and guidelines for data collection, analysis, and presentation of immunization safety dataSmall for gestational age: case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety dataLow birth weight: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety dataPreterm birth: case definition & guidelines for data collection, analysis, and presentation of immunisation safety dataNeonatal death: case definition & guidelines for data collection, analysis, and presentation of immunization safety dataFailure to thrive: case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data</div>
                            <small style="color: var(--text-muted)">12618248.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Explicitly stated that no multiplicity correction or formal hypothesis testing was performed for multiple tests (e.g., nominal P-values reported).</li><li>Includes exploratory or post hoc analyses which may inflate type I error.</li>
                                <li>...and 4 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Targeted therapy in advanced -mutated colorectal cancer: systematic review and network meta-analysis
-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic LandscapeClinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisBRAF mutation in metastatic colorectal cancerANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated 
-Mutant Metastatic Colorectal CancerMetastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upEuropean expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancerAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsCetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusFOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyUpfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialIndividual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal CancerFirst line therapy in stage IV BRAF mutated colorectal cancerPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerPIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFREncorafenib Plus Cetuximab as a New Standard of Care for Previously Treated  V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON StudyRandomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Encorafenib, Cetuximab, and mFOLFOX6 in -Mutated Colorectal CancerThe PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analysesPractical methods for incorporating summary time-to-event data into meta-analysis: updated guidancePractical methods for incorporating summary time-to-event data into meta-analysisRoB 2: a revised tool for assessing risk of bias in randomised trialsMethodological index for non-randomized studies (minors): development and validation of a new instrumentDevelopment, content validation, and reliability of the Assessment of Real-World Observational Studies (ArRoWS) critical appraisal toolGeneral Methods for Monitoring Convergence of Iterative SimulationsChecking consistency in mixed treatment comparison meta-analysisFOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 StudyBiweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX TrialFOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerBevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialThe influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trialCombined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial624P Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancerTunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I studyCobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With  Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPhase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancerCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerPilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patientsVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsA Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyUpdated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 studyDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialSafety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramBinimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With  V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer StudyA Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal CancerPhase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationA phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identificationEfficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trialBevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trialPhase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialMutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient OutcomeEfficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerFinal analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinomaFOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of 
-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) StudyLong-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal CancerImpact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyPhase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII studyFOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trialFOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trialVIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort StudyPhase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced <i>BRAF-</i>mutant colorectal cancer (<i>BRAFm</i> CRC)Combined BRAF, EGFR, and MEK Inhibition in Patients with 
-Mutant Colorectal CancerPanitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialAnalysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal CancerEncorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with <i>BRAF</i> V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practiceEncorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experienceEfficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter studyTreatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in ChinaWJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United StatesEncorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRCAdaptive mutability of colorectal cancers in response to targeted therapiesSEAMARK: randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC)Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer">Targeted therapy in advanced -mutated colorectal cancer: systematic review and network meta-analysis
-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic LandscapeClinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisBRAF mutation in metastatic colorectal cancerANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated 
-Mutant Metastatic Colorectal CancerMetastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upEuropean expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancerAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsCetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusFOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyUpfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialIndividual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal CancerFirst line therapy in stage IV BRAF mutated colorectal cancerPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerPIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFREncorafenib Plus Cetuximab as a New Standard of Care for Previously Treated  V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON StudyRandomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Encorafenib, Cetuximab, and mFOLFOX6 in -Mutated Colorectal CancerThe PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analysesPractical methods for incorporating summary time-to-event data into meta-analysis: updated guidancePractical methods for incorporating summary time-to-event data into meta-analysisRoB 2: a revised tool for assessing risk of bias in randomised trialsMethodological index for non-randomized studies (minors): development and validation of a new instrumentDevelopment, content validation, and reliability of the Assessment of Real-World Observational Studies (ArRoWS) critical appraisal toolGeneral Methods for Monitoring Convergence of Iterative SimulationsChecking consistency in mixed treatment comparison meta-analysisFOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 StudyBiweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX TrialFOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerBevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialThe influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trialCombined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial624P Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancerTunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I studyCobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With  Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPhase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancerCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerPilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patientsVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsA Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyUpdated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 studyDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialSafety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramBinimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With  V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer StudyA Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal CancerPhase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationA phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identificationEfficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trialBevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trialPhase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialMutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient OutcomeEfficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerFinal analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinomaFOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of 
-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) StudyLong-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal CancerImpact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyPhase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII studyFOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trialFOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trialVIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort StudyPhase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced <i>BRAF-</i>mutant colorectal cancer (<i>BRAFm</i> CRC)Combined BRAF, EGFR, and MEK Inhibition in Patients with 
-Mutant Colorectal CancerPanitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialAnalysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal CancerEncorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with <i>BRAF</i> V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practiceEncorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experienceEfficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter studyTreatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in ChinaWJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United StatesEncorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRCAdaptive mutability of colorectal cancers in response to targeted therapiesSEAMARK: randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC)Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer</div>
                            <small style="color: var(--text-muted)">12628362.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple treatment comparisons.</li><li>Categorical data mentioned, but no appropriate categorical tests (e.g., Chi-square) found.</li>
                                <li>...and 5 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreenMammographic density and the risk and detection of breast cancerMammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 yearsPriorities for the primary prevention of breast cancerIdentifying women with dense breasts at high risk for interval cancer: a cohort studyPrevalence of mammographically dense breasts in the United StatesDecade of ‘normal’ mammography reports--the happygramUS women must be told breast density after mammogram, says FDAShould we share breast density information during breast cancer screening in the United Kingdom? an integrative reviewBreast density notification: evidence on whether benefit outweighs harm is required to inform future screening practiceThe Impact of Breast Density Information or Notification on Women’s Cognitive, Psychological, and Behavioral Outcomes: A Systematic ReviewClinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwideSupplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task ForceSupplemental MRI Screening for Women with Extremely Dense Breast TissueComparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trialBreast cancer screening at a crossroads: supplemental imaging for dense breastsDetecting Breast Cancer in Women with Dense BreastsEnsuring Clarity and Understandability of the FDA’s Breast Density NotificationsPsychosocial outcomes and health service use after notifying women participating in population breast screening when they have dense breasts: a BreastScreen Queensland randomised controlled trialGeneral practitioners’ (GPs) understanding and views on breast density in Australia: a qualitative interview study“It’s about our bodies… we have the right to know this stuff”: A qualitative focus group study on Australian women’s perspectives on breast densityAustralian Women’s Intentions and Psychological Outcomes Related to Breast Density Notification and Information: A Randomized Clinical TrialBreast Density Awareness, Knowledge, and Attitudes Among US Women: National Survey Results Across 5 YearsProspective study of predictors of attendance for breast screening in inner LondonRelationships among breast cancer perceived absolute risk, comparative risk, and worriesDifferences in Breast Density Awareness, Knowledge, and Plans Based on State Legislation Status and Sociodemographic CharacteristicsWomen’s Understandings and Misunderstandings of Breast Density and Related Concepts: A Mixed Methods StudyDevelopment of a theory-informed questionnaire to assess the acceptability of healthcare interventionsPrior breast density awareness, knowledge, and communication in a health system-embedded behavioral intervention trialThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionThe Single Item Literacy Screener: evaluation of a brief instrument to identify limited reading abilityEliciting Medical Maximizing-Minimizing Preferences with a Single Question: Development and Validation of the MM1Do People Have Insight Into Their Abilities? A MetasynthesisBreast Density Notification: A Systematic Review of the Impact on Primary Care PractitionersEngaging Women with Limited Health Literacy in Mammography Decision-Making: Perspectives of Patients and Primary Care ProvidersSociodemographic Variations in Women’s Reports of Discussions With Clinicians About Breast DensityWomen’s responses to information on mammographic breast densityRandomized Trial of Personalized Breast Density and Breast Cancer Risk NotificationEffect of a Randomized Trial of a Web-Based Intervention on Patient-Provider Communication About Breast DensityEffectiveness of Breast Density Educational Interventions on Mammography Screening Adherence Among Underserved Latinas: A Randomized Controlled TrialA randomized trial to evaluate the impact of breast density notification on anxiety, breast cancer worry, and perceived risk among Latinas at a federally qualified health center : Breast density notification and anxiety, breast cancer worry, and perceived risk among LatinasSupplemental breast cancer screening after negative mammography in US women with dense breastsThe impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic reviewBreast density implications and supplemental screeningCost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue">Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreenMammographic density and the risk and detection of breast cancerMammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 yearsPriorities for the primary prevention of breast cancerIdentifying women with dense breasts at high risk for interval cancer: a cohort studyPrevalence of mammographically dense breasts in the United StatesDecade of ‘normal’ mammography reports--the happygramUS women must be told breast density after mammogram, says FDAShould we share breast density information during breast cancer screening in the United Kingdom? an integrative reviewBreast density notification: evidence on whether benefit outweighs harm is required to inform future screening practiceThe Impact of Breast Density Information or Notification on Women’s Cognitive, Psychological, and Behavioral Outcomes: A Systematic ReviewClinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwideSupplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task ForceSupplemental MRI Screening for Women with Extremely Dense Breast TissueComparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trialBreast cancer screening at a crossroads: supplemental imaging for dense breastsDetecting Breast Cancer in Women with Dense BreastsEnsuring Clarity and Understandability of the FDA’s Breast Density NotificationsPsychosocial outcomes and health service use after notifying women participating in population breast screening when they have dense breasts: a BreastScreen Queensland randomised controlled trialGeneral practitioners’ (GPs) understanding and views on breast density in Australia: a qualitative interview study“It’s about our bodies… we have the right to know this stuff”: A qualitative focus group study on Australian women’s perspectives on breast densityAustralian Women’s Intentions and Psychological Outcomes Related to Breast Density Notification and Information: A Randomized Clinical TrialBreast Density Awareness, Knowledge, and Attitudes Among US Women: National Survey Results Across 5 YearsProspective study of predictors of attendance for breast screening in inner LondonRelationships among breast cancer perceived absolute risk, comparative risk, and worriesDifferences in Breast Density Awareness, Knowledge, and Plans Based on State Legislation Status and Sociodemographic CharacteristicsWomen’s Understandings and Misunderstandings of Breast Density and Related Concepts: A Mixed Methods StudyDevelopment of a theory-informed questionnaire to assess the acceptability of healthcare interventionsPrior breast density awareness, knowledge, and communication in a health system-embedded behavioral intervention trialThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionThe Single Item Literacy Screener: evaluation of a brief instrument to identify limited reading abilityEliciting Medical Maximizing-Minimizing Preferences with a Single Question: Development and Validation of the MM1Do People Have Insight Into Their Abilities? A MetasynthesisBreast Density Notification: A Systematic Review of the Impact on Primary Care PractitionersEngaging Women with Limited Health Literacy in Mammography Decision-Making: Perspectives of Patients and Primary Care ProvidersSociodemographic Variations in Women’s Reports of Discussions With Clinicians About Breast DensityWomen’s responses to information on mammographic breast densityRandomized Trial of Personalized Breast Density and Breast Cancer Risk NotificationEffect of a Randomized Trial of a Web-Based Intervention on Patient-Provider Communication About Breast DensityEffectiveness of Breast Density Educational Interventions on Mammography Screening Adherence Among Underserved Latinas: A Randomized Controlled TrialA randomized trial to evaluate the impact of breast density notification on anxiety, breast cancer worry, and perceived risk among Latinas at a federally qualified health center : Breast density notification and anxiety, breast cancer worry, and perceived risk among LatinasSupplemental breast cancer screening after negative mammography in US women with dense breastsThe impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic reviewBreast density implications and supplemental screeningCost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue</div>
                            <small style="color: var(--text-muted)">12673659.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Explicitly stated that no multiplicity correction or formal hypothesis testing was performed for multiple tests (e.g., nominal P-values reported).</li><li>Parametric tests used without documented normality checks.</li>
                                <li>...and 4 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trialFirst-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialPembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyTislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trialPembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trialGEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (LBA79)First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trialPrimary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityPhase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer (LBA-5)Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 T cell responsesEfficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific, for CPI-naive metastatic NSCLC with PD-L1 1–49% or ≥50% (OA11.03)ARC-7: randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)Fc-silent anti-TIGIT antibodies potentiate antitumor immunity without depleting regulatory T cellsPreclinical characterization of GLS-010 (zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancerEfficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II studyEfficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II studyChemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitorsPhase 2 randomized study of domvanalimab combined with zimberelimab in front-line, PD-(L)1 high, locally advanced or metastatic non-small cell lung cancer (NSCLC): results from ARC-10 part 1STAR-221: a randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomaAnti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanismsRegulatory T cells in immune checkpoint blockade antitumor therapyFirst-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2−) locally advanced unresectable or metastatic gastric cancers: first report of GEMINI-Gastric sub study 2 (1422P)PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and Tumor Area Positivity across 28-8, 22C3, and SP263 assaysTumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoringConcordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samplesHigh interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinomaConcordance between the PD-L1 Tumor Area Positivity score and Combined Positive Score for gastric or esophageal cancers treated with tislelizumab">Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trialFirst-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialPembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyTislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trialPembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trialGEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (LBA79)First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trialPrimary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityPhase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer (LBA-5)Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 T cell responsesEfficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific, for CPI-naive metastatic NSCLC with PD-L1 1–49% or ≥50% (OA11.03)ARC-7: randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)Fc-silent anti-TIGIT antibodies potentiate antitumor immunity without depleting regulatory T cellsPreclinical characterization of GLS-010 (zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancerEfficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II studyEfficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II studyChemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitorsPhase 2 randomized study of domvanalimab combined with zimberelimab in front-line, PD-(L)1 high, locally advanced or metastatic non-small cell lung cancer (NSCLC): results from ARC-10 part 1STAR-221: a randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomaAnti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanismsRegulatory T cells in immune checkpoint blockade antitumor therapyFirst-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2−) locally advanced unresectable or metastatic gastric cancers: first report of GEMINI-Gastric sub study 2 (1422P)PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and Tumor Area Positivity across 28-8, 22C3, and SP263 assaysTumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoringConcordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samplesHigh interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinomaConcordance between the PD-L1 Tumor Area Positivity score and Combined Positive Score for gastric or esophageal cancers treated with tislelizumab</div>
                            <small style="color: var(--text-muted)">12705419.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Categorical data mentioned, but no appropriate categorical tests (e.g., Chi-square) found.</li>
                                <li>...and 6 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsisThe Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)Sepsis and septic shockTime to treatment and mortality during mandated emergency care for sepsisED door-to-antibiotic time and long-term mortality in sepsisImproving sepsis treatment by embracing diagnostic uncertaintyAssociation of appropriate empirical antimicrobial therapy with in-hospital mortality in patients with bloodstream infections in the USSurvival of critically ill patients hospitalized in and out of intensive careImpact of a deep learning sepsis prediction model on quality of care and survivalPredicting patient decompensation from continuous physiologic monitoring in the emergency departmentRobust classification of bacterial and viral infections via integrated host gene expression diagnosticsA comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene setA community approach to mortality prediction in sepsis via gene expression analysisA novel 29-messenger RNA host-response assay from whole blood accurately identifies bacterial and viral infections in patients presenting to the emergency department with suspected infections: a prospective observational studyA 29-mRNA host response test from blood accurately distinguishes bacterial and viral infections among emergency department patientsA 29-mRNA host response whole-blood signature improves prediction of 28-day mortality and 7-day intensive care unit care in adults presenting to the emergency department with suspected acute infection and/or sepsisA standardized protocol using clinical adjudication to define true infection status in patients presenting to the emergency department with suspected infections and/or sepsisA quantitative study of decision thresholds for initiation of antibiotics in suspected sepsisEarly administration of antibiotics for suspected sepsis.Antimicrobial stewardship in the emergency departmentAssociation of adverse events with antibiotic use in hospitalized patientsTarget product profile for a diagnostic assay to differentiate between bacterial and non-bacterial infections and reduce antimicrobial overuse in resource-limited settings: an expert consensusDiagnostic accuracy of a bacterial and viral biomarker point-of-care test in the outpatient settingMeMed BV testing in emergency department patients presenting with febrile illness concerning for respiratory tract infectionUsing a 29-mRNA host response classifier to detect bacterial coinfections and predict outcomes in COVID-19 patients presenting to the emergency departmentDetection of viral infection and bacterial coinfection and superinfection in coronavirus disease 2019 patients presenting to the emergency department using the 29-mRNA host response classifier IMX-BVN-3: a multicenter studyThe role for policy in AI-assisted medical diagnosisImpact of the Centers for Medicare and Medicaid Services sepsis core measure on antibiotic usePrognostic accuracy of Sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency departmentMitigating structural racism to reduce inequities in sepsis outcomes: a mixed methods, longitudinal intervention studyA host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation studyHost test based on tumor necrosis factor-related apoptosis-inducing ligand, interferon gamma-induced protein-10 and C-reactive protein for differentiating bacterial and viral respiratory tract infections in adults: diagnostic accuracy studyA rapid host–protein test for differentiating bacterial from viral infection: Apollo diagnostic accuracy studyDevelopment of machine learning classifiers for blood-based diagnosis and prognosis of suspected acute infections and sepsisA generalizable 29-mRNA neural-network classifier for acute bacterial and viral infectionsA transcriptomic severity metric that predicts clinical outcomes in critically ill surgical sepsis patientsEvaluation of a multivalent transcriptomic metric for diagnosing surgical sepsis and estimating mortality among critically ill patientsDiagnostic host gene expression analysis by quantitative reverse transcription loop-mediated isothermal amplification to discriminate between bacterial and viral infections">Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsisThe Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)Sepsis and septic shockTime to treatment and mortality during mandated emergency care for sepsisED door-to-antibiotic time and long-term mortality in sepsisImproving sepsis treatment by embracing diagnostic uncertaintyAssociation of appropriate empirical antimicrobial therapy with in-hospital mortality in patients with bloodstream infections in the USSurvival of critically ill patients hospitalized in and out of intensive careImpact of a deep learning sepsis prediction model on quality of care and survivalPredicting patient decompensation from continuous physiologic monitoring in the emergency departmentRobust classification of bacterial and viral infections via integrated host gene expression diagnosticsA comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene setA community approach to mortality prediction in sepsis via gene expression analysisA novel 29-messenger RNA host-response assay from whole blood accurately identifies bacterial and viral infections in patients presenting to the emergency department with suspected infections: a prospective observational studyA 29-mRNA host response test from blood accurately distinguishes bacterial and viral infections among emergency department patientsA 29-mRNA host response whole-blood signature improves prediction of 28-day mortality and 7-day intensive care unit care in adults presenting to the emergency department with suspected acute infection and/or sepsisA standardized protocol using clinical adjudication to define true infection status in patients presenting to the emergency department with suspected infections and/or sepsisA quantitative study of decision thresholds for initiation of antibiotics in suspected sepsisEarly administration of antibiotics for suspected sepsis.Antimicrobial stewardship in the emergency departmentAssociation of adverse events with antibiotic use in hospitalized patientsTarget product profile for a diagnostic assay to differentiate between bacterial and non-bacterial infections and reduce antimicrobial overuse in resource-limited settings: an expert consensusDiagnostic accuracy of a bacterial and viral biomarker point-of-care test in the outpatient settingMeMed BV testing in emergency department patients presenting with febrile illness concerning for respiratory tract infectionUsing a 29-mRNA host response classifier to detect bacterial coinfections and predict outcomes in COVID-19 patients presenting to the emergency departmentDetection of viral infection and bacterial coinfection and superinfection in coronavirus disease 2019 patients presenting to the emergency department using the 29-mRNA host response classifier IMX-BVN-3: a multicenter studyThe role for policy in AI-assisted medical diagnosisImpact of the Centers for Medicare and Medicaid Services sepsis core measure on antibiotic usePrognostic accuracy of Sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency departmentMitigating structural racism to reduce inequities in sepsis outcomes: a mixed methods, longitudinal intervention studyA host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation studyHost test based on tumor necrosis factor-related apoptosis-inducing ligand, interferon gamma-induced protein-10 and C-reactive protein for differentiating bacterial and viral respiratory tract infections in adults: diagnostic accuracy studyA rapid host–protein test for differentiating bacterial from viral infection: Apollo diagnostic accuracy studyDevelopment of machine learning classifiers for blood-based diagnosis and prognosis of suspected acute infections and sepsisA generalizable 29-mRNA neural-network classifier for acute bacterial and viral infectionsA transcriptomic severity metric that predicts clinical outcomes in critically ill surgical sepsis patientsEvaluation of a multivalent transcriptomic metric for diagnosing surgical sepsis and estimating mortality among critically ill patientsDiagnostic host gene expression analysis by quantitative reverse transcription loop-mediated isothermal amplification to discriminate between bacterial and viral infections</div>
                            <small style="color: var(--text-muted)">12705421.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Parametric tests used without documented normality checks.</li>
                                <li>...and 4 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialThe role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversiesTreatment guidelines in psoriatic arthritisTargeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomesExperiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower registryImpact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and EuropeGroup for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritisEULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 updateMinimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumabMeasurement properties of the minimal disease activity criteria for psoriatic arthritisPrevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysisPhenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapyRole of Th17 cells in human autoimmune arthritisIL-17 receptor and its functional significance in psoriatic arthritisTargeting IL-17 in psoriatic arthritisDual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammationInterleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritisLong-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyBimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitisPathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathiesHeterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complexBimekizumab versus secukinumab in plaque psoriasisBimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patientsProgress in intra-articular therapyPermeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammationThe therapeutic potential of NanobodiesImproved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody TechnologyNanobodies and nanobody-based human heavy chain antibodies as antitumor therapeuticsNaturally occurring antibodies devoid of light chainsInfluence of molecular size on tissue distribution of antibody fragmentsA novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritisIL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b studyA randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasisComparative genomic profiling of synovium versus skin lesions in psoriatic arthritisEfficacy and safety of ixekizumab with or without methotrexate in biologic-naïve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H studyPatient-reported outcomes in psoriatic arthritisA multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritisAchieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivitySecukinumab inhibition of interleukin-17A in patients with psoriatic arthritisIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialTrial of upadacitinib and adalimumab for psoriatic arthritisDifferential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic diseaseComparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisBimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17FFormatted anti-tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritisPsychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trialsSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialAdverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping reviewSuppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing T cells through modification of the intestinal microbiotaTH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitisDivergent functions of IL-17-family cytokines in DSS colitis: insights from a naturally-occurring human mutation in IL-17FRisk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sourcesA review of the safety of interleukin-17A inhibitor secukinumabLong-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance dataLong-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsSafety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trialsSex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysisResponses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trialsAxial involvement in psoriatic arthritis: is it unique?American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritisA 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisA patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative">Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialThe role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversiesTreatment guidelines in psoriatic arthritisTargeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomesExperiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower registryImpact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and EuropeGroup for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritisEULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 updateMinimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumabMeasurement properties of the minimal disease activity criteria for psoriatic arthritisPrevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysisPhenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapyRole of Th17 cells in human autoimmune arthritisIL-17 receptor and its functional significance in psoriatic arthritisTargeting IL-17 in psoriatic arthritisDual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammationInterleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritisLong-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyBimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitisPathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathiesHeterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complexBimekizumab versus secukinumab in plaque psoriasisBimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patientsProgress in intra-articular therapyPermeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammationThe therapeutic potential of NanobodiesImproved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody TechnologyNanobodies and nanobody-based human heavy chain antibodies as antitumor therapeuticsNaturally occurring antibodies devoid of light chainsInfluence of molecular size on tissue distribution of antibody fragmentsA novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritisIL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b studyA randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasisComparative genomic profiling of synovium versus skin lesions in psoriatic arthritisEfficacy and safety of ixekizumab with or without methotrexate in biologic-naïve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H studyPatient-reported outcomes in psoriatic arthritisA multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritisAchieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivitySecukinumab inhibition of interleukin-17A in patients with psoriatic arthritisIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialTrial of upadacitinib and adalimumab for psoriatic arthritisDifferential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic diseaseComparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisBimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17FFormatted anti-tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritisPsychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trialsSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialAdverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping reviewSuppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing T cells through modification of the intestinal microbiotaTH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitisDivergent functions of IL-17-family cytokines in DSS colitis: insights from a naturally-occurring human mutation in IL-17FRisk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sourcesA review of the safety of interleukin-17A inhibitor secukinumabLong-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance dataLong-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsSafety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trialsSex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysisResponses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trialsAxial involvement in psoriatic arthritis: is it unique?American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritisA 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisA patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative</div>
                            <small style="color: var(--text-muted)">12705426.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Includes exploratory or post hoc analyses which may inflate type I error.</li><li>P-values reported without corresponding effect sizes or measures of magnitude.</li>
                                <li>...and 5 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Brain activity associated with breakthrough food preoccupation in an individual on tirzepatideOverlapping brain circuits for homeostatic and hedonic feedingReward mechanisms in obesity: new insights and future directionsAn orexigenic subnetwork within the human hippocampusBlaming the brain for obesity: integration of hedonic and homeostatic mechanismsThe insulo-opercular cortex encodes food-specific content under controlled and naturalistic conditionsHow may GIP enhance the therapeutic efficacy of GLP-1?GLP-1 and weight loss: unraveling the diverse neural circuitryPotent incretin-based therapy for obesity: a systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safetyA pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorderGLP-1 receptor agonists: a novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic reviewWhat is food noise? A conceptual model of food cue reactivityLoss of control over eating predicts outcomes in bariatric surgery patients: a prospective, 24-month follow-up studyPreoccupation in bulimia nervosa, binge-eating disorder, anorexia nervosa, and higher weightBinge eating disorderFood-related impulsivity in obesity and binge eating disorder–a systematic reviewThe neurobiology of binge-eating disorder compared with obesity: implications for differential therapeuticsHuman habit neural circuitry may be perturbed in eating disordersEffects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trialTwo-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5Closed-loop neuromodulation in an individual with treatment-resistant depressionPilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eatingResponsive deep brain stimulation guided by ventral striatal electrophysiology of obsession durably ameliorates compulsionBrain-responsive neurostimulation for loss of control eating: early feasibility studyClosing the loop on impulsivity via nucleus accumbens delta-band activity in mice and manOptimal detection of changepoints with a linear computational costUsing penalized contrasts for the change-point problemSub-acute delayed failure of subthalamic DBS in Parkinson’s disease: the role of micro-lesion effectTirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trialCingulate dynamics track depression recovery with deep brain stimulationAn electroencephalographic signature predicts antidepressant response in major depressionLong-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorderSubthalamic nucleus deep brain stimulation in the beta frequency range boosts cortical beta oscillations and slows down movementDeep brain stimulation of the subthalamic nucleus alters the cortical profile of response inhibition in the beta frequency band: a scalp EEG study in Parkinson’s diseaseThe eating disorder examination: a semi-structured interview for the assessment of the specific psychopathology of eating disordersAppetitive mapping of the human nucleus accumbensAberrant impulse control circuitry in obesityFieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data">Brain activity associated with breakthrough food preoccupation in an individual on tirzepatideOverlapping brain circuits for homeostatic and hedonic feedingReward mechanisms in obesity: new insights and future directionsAn orexigenic subnetwork within the human hippocampusBlaming the brain for obesity: integration of hedonic and homeostatic mechanismsThe insulo-opercular cortex encodes food-specific content under controlled and naturalistic conditionsHow may GIP enhance the therapeutic efficacy of GLP-1?GLP-1 and weight loss: unraveling the diverse neural circuitryPotent incretin-based therapy for obesity: a systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safetyA pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorderGLP-1 receptor agonists: a novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic reviewWhat is food noise? A conceptual model of food cue reactivityLoss of control over eating predicts outcomes in bariatric surgery patients: a prospective, 24-month follow-up studyPreoccupation in bulimia nervosa, binge-eating disorder, anorexia nervosa, and higher weightBinge eating disorderFood-related impulsivity in obesity and binge eating disorder–a systematic reviewThe neurobiology of binge-eating disorder compared with obesity: implications for differential therapeuticsHuman habit neural circuitry may be perturbed in eating disordersEffects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trialTwo-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5Closed-loop neuromodulation in an individual with treatment-resistant depressionPilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eatingResponsive deep brain stimulation guided by ventral striatal electrophysiology of obsession durably ameliorates compulsionBrain-responsive neurostimulation for loss of control eating: early feasibility studyClosing the loop on impulsivity via nucleus accumbens delta-band activity in mice and manOptimal detection of changepoints with a linear computational costUsing penalized contrasts for the change-point problemSub-acute delayed failure of subthalamic DBS in Parkinson’s disease: the role of micro-lesion effectTirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trialCingulate dynamics track depression recovery with deep brain stimulationAn electroencephalographic signature predicts antidepressant response in major depressionLong-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorderSubthalamic nucleus deep brain stimulation in the beta frequency range boosts cortical beta oscillations and slows down movementDeep brain stimulation of the subthalamic nucleus alters the cortical profile of response inhibition in the beta frequency band: a scalp EEG study in Parkinson’s diseaseThe eating disorder examination: a semi-structured interview for the assessment of the specific psychopathology of eating disordersAppetitive mapping of the human nucleus accumbensAberrant impulse control circuitry in obesityFieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data</div>
                            <small style="color: var(--text-muted)">12705427.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Longitudinal or clustered data structures detected without corresponding hierarchical or mixed-effects modeling.</li>
                                <li>...and 8 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="A consensus blood transcriptomic framework for sepsisGlobal, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease StudySepsis and septic shockEnhancing recovery from sepsis: a reviewWhy have clinical trials in sepsis failed?Sepsis therapies: learning from 30 years of failure of translational research to propose new leadsThe immunology of sepsisThe immunopathology of sepsis and potential therapeutic targetsGenomic landscape of the individual host response and outcomes in sepsis: a prospective cohort studyClassification of patients with sepsis according to blood genomic endotype: a prospective cohort studyShared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumoniaUnsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clustersPrognostic and predictive enrichment in sepsisTranscriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trialInterleukin-6 receptor antagonists in critically Ill patients with Covid-19Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trialTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialRisk stratification and prognosis in sepsis: What have we learned from microarrays?Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicineAn immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expressionThe leukocyte non-coding RNA landscape in critically ill patients with sepsiseQTLs identify regulatory networks and drivers of variation in the individual response to sepsisSilhouettes: a graphical aid to the interpretation and validation of cluster analysisControlling the false discovery rate: a practical and powerful approach to multiple testing.Multidimensional analysis of the host response reveals prognostic and pathogen-driven immune subtypes among adults with sepsis in UgandaEffect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trialNeutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsisSCENIC: single-cell regulatory network inference and clusteringSepsis subclasses: a framework for development and interpretationReframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapiesUncovering heterogeneity in sepsis: a comparative analysis of subphenotypesDiscovering transcriptional signatures of disease for diagnosis versus mechanismBroad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsisMolecular biomarker to assist in diagnosing abdominal sepsis upon ICU admissionA molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admissionA generalizable 29-mRNA neural-network classifier for acute bacterial and viral infectionsAssociation of dendritic cell signatures with autoimmune inflammation revealed by single‐cell profiling.A CD8 T cell transcription signature predicts prognosis in autoimmune disease.Comparison of two rapid host-response tests for distinguishing bacterial and viral infection in adults with acute respiratory infectionA rapid host response blood test for bacterial/viral infection discrimination using a portable molecular diagnostic platformParadoxical roles of the neutrophil in sepsis: protective and deleteriousPAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shockNETosis: how vital is it?The role of platelets in sepsisThe role of eosinophils in sepsis and acute respiratory distress syndrome: a scoping reviewThe pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescenceHeme-derived metabolic signals dictate immune responsesCritical illness-related corticosteroid insufficiency: latest pathophysiology and management guidelinesIdentification of key immune-related genes in the progression of septic shockDexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cellsPrednisolone dose-dependently influences inflammation and coagulation during human endotoxemiaaffy—analysis of Affymetrix GeneChip data at the probe levelThe sva package for removing batch effects and other unwanted variation in high-throughput experimentsA framework for oligonucleotide microarray preprocessingfeatureCounts: an efficient general purpose program for assigning sequence reads to genomic featuresFast gapped-read alignment with Bowtie 2Leukocyte transcriptional signatures dependent on LPS dosage in human endotoxemiaMapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRtIdentifying functional modules in interaction networks through overlapping Markov clusteringCMA: a comprehensive Bioconductor package for supervised classification with high dimensional dataConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingGene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profilesBiomarkers of sepsis: time for a reappraisalUnderstanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis">A consensus blood transcriptomic framework for sepsisGlobal, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease StudySepsis and septic shockEnhancing recovery from sepsis: a reviewWhy have clinical trials in sepsis failed?Sepsis therapies: learning from 30 years of failure of translational research to propose new leadsThe immunology of sepsisThe immunopathology of sepsis and potential therapeutic targetsGenomic landscape of the individual host response and outcomes in sepsis: a prospective cohort studyClassification of patients with sepsis according to blood genomic endotype: a prospective cohort studyShared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumoniaUnsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clustersPrognostic and predictive enrichment in sepsisTranscriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trialInterleukin-6 receptor antagonists in critically Ill patients with Covid-19Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trialTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialRisk stratification and prognosis in sepsis: What have we learned from microarrays?Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicineAn immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expressionThe leukocyte non-coding RNA landscape in critically ill patients with sepsiseQTLs identify regulatory networks and drivers of variation in the individual response to sepsisSilhouettes: a graphical aid to the interpretation and validation of cluster analysisControlling the false discovery rate: a practical and powerful approach to multiple testing.Multidimensional analysis of the host response reveals prognostic and pathogen-driven immune subtypes among adults with sepsis in UgandaEffect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trialNeutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsisSCENIC: single-cell regulatory network inference and clusteringSepsis subclasses: a framework for development and interpretationReframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapiesUncovering heterogeneity in sepsis: a comparative analysis of subphenotypesDiscovering transcriptional signatures of disease for diagnosis versus mechanismBroad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsisMolecular biomarker to assist in diagnosing abdominal sepsis upon ICU admissionA molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admissionA generalizable 29-mRNA neural-network classifier for acute bacterial and viral infectionsAssociation of dendritic cell signatures with autoimmune inflammation revealed by single‐cell profiling.A CD8 T cell transcription signature predicts prognosis in autoimmune disease.Comparison of two rapid host-response tests for distinguishing bacterial and viral infection in adults with acute respiratory infectionA rapid host response blood test for bacterial/viral infection discrimination using a portable molecular diagnostic platformParadoxical roles of the neutrophil in sepsis: protective and deleteriousPAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shockNETosis: how vital is it?The role of platelets in sepsisThe role of eosinophils in sepsis and acute respiratory distress syndrome: a scoping reviewThe pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescenceHeme-derived metabolic signals dictate immune responsesCritical illness-related corticosteroid insufficiency: latest pathophysiology and management guidelinesIdentification of key immune-related genes in the progression of septic shockDexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cellsPrednisolone dose-dependently influences inflammation and coagulation during human endotoxemiaaffy—analysis of Affymetrix GeneChip data at the probe levelThe sva package for removing batch effects and other unwanted variation in high-throughput experimentsA framework for oligonucleotide microarray preprocessingfeatureCounts: an efficient general purpose program for assigning sequence reads to genomic featuresFast gapped-read alignment with Bowtie 2Leukocyte transcriptional signatures dependent on LPS dosage in human endotoxemiaMapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRtIdentifying functional modules in interaction networks through overlapping Markov clusteringCMA: a comprehensive Bioconductor package for supervised classification with high dimensional dataConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingGene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profilesBiomarkers of sepsis: time for a reappraisalUnderstanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis</div>
                            <small style="color: var(--text-muted)">12705454.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Includes exploratory or post hoc analyses which may inflate type I error.</li>
                                <li>...and 7 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trialAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaAdjuvant pembrolizumab versus placebo in resected stage III melanomaFive-year analysis of adjuvant pembrolizumab or placebo in stage III melanomaFinal results for adjuvant dabrafenib plus trametinib in stage III melanomaAdjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results for CheckMate 238Relatlimab and nivolumab versus nivolumab in untreated advanced melanomaOverall survival and response with nivolumab and relatlimab in advanced melanomaNivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateNeoadjuvant relatlimab and nivolumab in resectable melanomaNeoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trialNeoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trialNeoadjuvant anti–PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trialAdjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB–D or stage IV melanoma (CheckMate 915)Neoadjuvant nivolumab and ipilimumab in resectable stage III melanomaIndividualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomized, phase 2b study">Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trialAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaAdjuvant pembrolizumab versus placebo in resected stage III melanomaFive-year analysis of adjuvant pembrolizumab or placebo in stage III melanomaFinal results for adjuvant dabrafenib plus trametinib in stage III melanomaAdjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results for CheckMate 238Relatlimab and nivolumab versus nivolumab in untreated advanced melanomaOverall survival and response with nivolumab and relatlimab in advanced melanomaNivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateNeoadjuvant relatlimab and nivolumab in resectable melanomaNeoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trialNeoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trialNeoadjuvant anti–PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trialAdjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB–D or stage IV melanoma (CheckMate 915)Neoadjuvant nivolumab and ipilimumab in resectable stage III melanomaIndividualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomized, phase 2b study</div>
                            <small style="color: var(--text-muted)">12705465.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Categorical data mentioned, but no appropriate categorical tests (e.g., Chi-square) found.</li>
                                <li>...and 5 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trialMolecular portraits of human breast tumoursTriple-negative breast cancerNeoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyEvolution of adjuvant chemotherapy for breast cancerWeekly paclitaxel in the adjuvant treatment of breast cancerLong-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast CancerFluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialRandomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trialsPhase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialSWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialImpact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast CancerLong-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trialAddition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialRandomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpressionLong-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancerComparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsCisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trialAdjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysisHuman Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline UpdateAmerican Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerCONSORT 2025 statement: updated guideline for reporting randomised trialsAnthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trialsOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerAdjuvant Olaparib for Patients with - or -Mutated Breast CancerInherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancerCamrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical TrialPembrolizumab and chemotherapy in high-risk, early-stage, ER/HER2 breast cancer: a randomized phase 3 trialPathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyNeoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialAdjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialA-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapyEffect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialPlatinum chemotherapy for early triple-negative breast cancerNeoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialEffect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical TrialA randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trialPEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancerNRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBCKi67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trialPrognostic predictive value of Ki-67 in stage I-II triple-negative breast cancerDe-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialBlinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerA randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursPembrolizumab for early triple-negative breast cancer">Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trialMolecular portraits of human breast tumoursTriple-negative breast cancerNeoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyEvolution of adjuvant chemotherapy for breast cancerWeekly paclitaxel in the adjuvant treatment of breast cancerLong-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast CancerFluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialRandomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trialsPhase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialSWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialImpact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast CancerLong-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trialAddition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialRandomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpressionLong-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancerComparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsCisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trialAdjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysisHuman Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline UpdateAmerican Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerCONSORT 2025 statement: updated guideline for reporting randomised trialsAnthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trialsOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerAdjuvant Olaparib for Patients with - or -Mutated Breast CancerInherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancerCamrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical TrialPembrolizumab and chemotherapy in high-risk, early-stage, ER/HER2 breast cancer: a randomized phase 3 trialPathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyNeoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialAdjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialA-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapyEffect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialPlatinum chemotherapy for early triple-negative breast cancerNeoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialEffect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical TrialA randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trialPEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancerNRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBCKi67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trialPrognostic predictive value of Ki-67 in stage I-II triple-negative breast cancerDe-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialBlinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerA randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursPembrolizumab for early triple-negative breast cancer</div>
                            <small style="color: var(--text-muted)">12723525.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Categorical data mentioned, but no appropriate categorical tests (e.g., Chi-square) found.</li>
                                <li>...and 7 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                    <tr>
                        <td>
                            <div class="truncate" title="Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trialTo test or not to test? A framework for counselling patients on preimplantation genetic testing for aneuploidy (PGT-A)Idiopathic recurrent miscarriage is caused mostly by aneuploid embryosLive birth with or without preimplantation genetic testing for aneuploidyMale infertilitySevere male factor in  fertilization: definition, prevalence, and treatment. An updateIntracytoplasmic sperm injection for male infertility and consequences for offspringInternational committee for monitoring assisted reproductive technologies world report: assisted reproductive technology 2008, 2009 and 2010Use of suboptimal sperm increases the risk of aneuploidy of the sex chromosomes in preimplantation blastocyst embryosFrequency, morbidity and equity - the case for increased research on male fertilityIntracytoplasmic sperm injection versus conventional in-vitro fertilisation for couples with infertility with non-severe male factor: a multicentre, open-label, randomised controlled trialPreimplantation genetic testing for aneuploidy in severe male factor infertilityComparison of preimplantation genetic testing for aneuploidy versus intracytoplasmic sperm injection in severe male infertilityWomen’s preferences concerning IVF treatment: a discrete choice experiment with particular focus on embryo transfer policyPreimplantation genetic testing for aneuploidy in severe male factor infertility: protocol for a multicenter randomised controlled trialAntisperm Antibody Testing: A Comprehensive Review of Its Role in the Management of Immunological Male Infertility and Results of a Global Survey of Clinical PracticesBlastocyst culture and transfer: analysis of results and parameters affecting outcome in two in vitro fertilization programsFrozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trialThe use of copy number loads to designate mosaicism in blastocyst stage PGT-A cycles: fewer is betterDeveloping a core outcome set for future infertility research: an international consensus development studyMultiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in JapanNeither relevant nor randomized: the use of “per embryo transfer” in the analysis of preimplantation genetic testing for aneuploidy trialsDiagnosis and treatment of infertility in men: AUA/ASRM guideline part IIThe diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunitiesEffect of the male factor on the clinical outcome of intracytoplasmic sperm injection combined with preimplantation aneuploidy testing: observational longitudinal cohort study of 1,219 consecutive cyclesDo sperm factors influence embryonic aneuploidy? Long live the oocyteThe use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinionFrom oocytes to a live birth: Are we improving the biological efficiency?Noninvasive preimplantation genetic testing for aneuploidy in spent medium may be more reliable than trophectoderm biopsySteady morphokinetic progression is an independent predictor of live birth: a descriptive reference for euploid embryosImpact of trophectoderm biopsy for preimplantation genetic testing on obstetric and neonatal outcomes: a meta-analysisPreimplantation genetic testing and child health: a national register-based study">Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trialTo test or not to test? A framework for counselling patients on preimplantation genetic testing for aneuploidy (PGT-A)Idiopathic recurrent miscarriage is caused mostly by aneuploid embryosLive birth with or without preimplantation genetic testing for aneuploidyMale infertilitySevere male factor in  fertilization: definition, prevalence, and treatment. An updateIntracytoplasmic sperm injection for male infertility and consequences for offspringInternational committee for monitoring assisted reproductive technologies world report: assisted reproductive technology 2008, 2009 and 2010Use of suboptimal sperm increases the risk of aneuploidy of the sex chromosomes in preimplantation blastocyst embryosFrequency, morbidity and equity - the case for increased research on male fertilityIntracytoplasmic sperm injection versus conventional in-vitro fertilisation for couples with infertility with non-severe male factor: a multicentre, open-label, randomised controlled trialPreimplantation genetic testing for aneuploidy in severe male factor infertilityComparison of preimplantation genetic testing for aneuploidy versus intracytoplasmic sperm injection in severe male infertilityWomen’s preferences concerning IVF treatment: a discrete choice experiment with particular focus on embryo transfer policyPreimplantation genetic testing for aneuploidy in severe male factor infertility: protocol for a multicenter randomised controlled trialAntisperm Antibody Testing: A Comprehensive Review of Its Role in the Management of Immunological Male Infertility and Results of a Global Survey of Clinical PracticesBlastocyst culture and transfer: analysis of results and parameters affecting outcome in two in vitro fertilization programsFrozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trialThe use of copy number loads to designate mosaicism in blastocyst stage PGT-A cycles: fewer is betterDeveloping a core outcome set for future infertility research: an international consensus development studyMultiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in JapanNeither relevant nor randomized: the use of “per embryo transfer” in the analysis of preimplantation genetic testing for aneuploidy trialsDiagnosis and treatment of infertility in men: AUA/ASRM guideline part IIThe diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunitiesEffect of the male factor on the clinical outcome of intracytoplasmic sperm injection combined with preimplantation aneuploidy testing: observational longitudinal cohort study of 1,219 consecutive cyclesDo sperm factors influence embryonic aneuploidy? Long live the oocyteThe use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinionFrom oocytes to a live birth: Are we improving the biological efficiency?Noninvasive preimplantation genetic testing for aneuploidy in spent medium may be more reliable than trophectoderm biopsySteady morphokinetic progression is an independent predictor of live birth: a descriptive reference for euploid embryosImpact of trophectoderm biopsy for preimplantation genetic testing on obstetric and neonatal outcomes: a meta-analysisPreimplantation genetic testing and child health: a national register-based study</div>
                            <small style="color: var(--text-muted)">12723751.json</small>
                        </td>
                        <td>
                            <span class="score-pill score-low">1.0</span>
                        </td>
                        <td>
                            <ul class="gaps-list">
                                <li>Missing explicit multiplicity correction despite multiple comparative tests or subgroup analyses.</li><li>Includes exploratory or post hoc analyses which may inflate type I error.</li>
                                <li>...and 6 more</li>
                            </ul>
                        </td>
                    </tr>
                    
                </tbody>
            </table>
        </section>

        <footer>
            Generated by StatsRecommender Auditor &bull; 2025
        </footer>
    </div>
</body>
</html>
    